Altamira Therapeutics (CYTOF) 20-F 14 Mar 19 2018 FY Annual report (foreign) Financial data

Document and Entity Information

Document and Entity Information	12 Months Ended
	Dec. 31, 2018shares
Document and Entity Information [Abstract]
Entity Registrant Name	AURIS MEDICAL HOLDING AG
Entity Central Index Key	0001601936
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Document Type	20-F
Document Period End Date	Dec. 31, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Common Stock, Shares Outstanding	37,495,859

Consolidated Statement of Profi

Consolidated Statement of Profit or Loss and Other Comprehensive Income (Loss) - CHF (SFr)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Profit or loss [abstract]
Research and development	SFr (6,689,589)	SFr (19,210,842)	SFr (24,776,763)
General and administrative	(4,264,534)	(5,150,409)	(5,446,512)
Operating loss	(10,954,123)	(24,361,251)	(30,223,275)
Interest income	0	53,570	67,565
Interest expense	(1,070,177)	(1,640,394)	(828,547)
Foreign currency exchange loss, net	(139,870)	(824,592)	(100,097)
Revaluation gain from derivative financial instruments	1,350,071	3,372,186	291,048
Transaction costs	(520,125)	(1,026,766)	0
Loss before tax	(11,334,224)	(24,427,247)	(30,793,306)
Income tax gain/(loss)	(162,177)	17,773	131,055
Net loss attributable to owners of the Company	(11,496,401)	(24,409,474)	(30,662,251)
Items that will never be reclassified to profit or loss
Remeasurements of defined benefit liability, net of taxes of CHF 0	1,277,192	271,980	(394,102)
Items that are or may be reclassified to profit or loss
Foreign currency translation differences, net of taxes of CHF 0	(10,964)	50,497	(19,723)
Other comprehensive income/(loss), net of taxes of CHF 0	1,266,228	322,477	(413,825)
Total comprehensive loss attributable to owners of the Company	SFr (10,230,173)	SFr (24,086,997)	SFr (31,076,076)
Basic and diluted loss per share (in chf per share)	SFr (0.72)	SFr (5.58)	SFr (8.93)

Consolidated Statement of Pro_2

Consolidated Statement of Profit or Loss and Other Comprehensive Income (Loss) (Parenthetical) - CHF (SFr)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Profit or loss [abstract]
Remeasurement of defined benefit plans, tax	SFr 0	SFr 0	SFr 0
Foreign currency translation differences, tax	0	0	0
Income tax relating to components of other comprehensive income	SFr 0	SFr 0	SFr 0

Consolidated Statement of Finan

Consolidated Statement of Financial Position - CHF (SFr)	Dec. 31, 2018	Dec. 31, 2017
Non-current assets
Property and equipment	SFr 33,895	SFr 252,899
Intangible assets	3,535,240	1,629,100
Derivative financial instruments	226,865	0
Other non-current receivables	16,001	76,710
Total non-current assets	3,812,001	1,958,709
Current assets
Other receivables	320,374	241,281
Prepayments	351,283	652,913
Cash and cash equivalents	5,393,207	14,973,369
Total current assets	6,064,864	15,867,563
Total assets	9,876,865	17,826,272
Equity
Share capital	710,336	19,349,556
Share premium	149,286,723	114,648,228
Foreign currency translation reserve	(44,011)	(33,047)
Accumulated deficit	(146,303,398)	(136,126,946)
Total shareholders' (deficit)/equity attributable to owners of the Company	3,649,650	(2,162,209)
Non-current liabilities
Loan	0	5,584,297
Derivative financial instruments	675,328	1,836,763
Employee benefit liability	648,287	1,962,970
Deferred tax liabilities	340,986	178,809
Total non-current liabilities	1,664,601	9,562,839
Current liabilities
Loan	1,435,400	4,542,109
Trade and other payables	1,836,335	1,200,820
Accrued expenses	1,290,879	4,682,713
Total current liabilities	4,562,614	10,425,642
Total liabilities	6,227,215	19,988,481
Total equity and liabilities	SFr 9,876,865	SFr 17,826,272

Consolidated Statement of Chang

Consolidated Statement of Changes in Equity - CHF (SFr)	Total	Share Capital	Share Premium	Foreign Currency Translation Reserve	Accumulated Deficit
Balance at beginning of period at Dec. 31, 2015	SFr 44,741,912	SFr 13,721,556	SFr 112,662,910	SFr (63,821)	SFr (81,578,733)
Other comprehensive income/(loss):
Net loss	(30,662,251)				(30,662,251)
Other comprehensive loss	(413,825)			(19,723)	(394,102)
Total comprehensive loss attributable to owners of the Company	(31,076,076)			(19,723)	(31,056,353)
Issue of bonus shares	188,092	10,325	177,767
Share issuance costs	(1,862)		(1,862)
Share based payments	290,783				290,783
Balance at end of period at Dec. 31, 2016	14,142,849	13,731,881	112,838,815	(83,544)	(112,344,303)
Other comprehensive income/(loss):
Net loss	(24,409,474)				(24,409,474)
Other comprehensive loss	322,477			50,497	271,980
Total comprehensive loss attributable to owners of the Company	(24,086,997)			50,497	(24,137,494)
Issue of ordinary shares associated with Initial Public Offering (IPO) and follow-on offering	7,948,603	5,617,675	2,330,928
Transaction costs	(521,515)		(521,515)
Share based payments	354,851				354,851
Balance at end of period at Dec. 31, 2017	(2,162,209)	19,349,556	114,648,228	(33,047)	(136,126,946)
Other comprehensive income/(loss):
Net loss	(11,496,401)				(11,496,401)
Other comprehensive loss	1,266,228			(10,964)	1,277,192
Total comprehensive loss attributable to owners of the Company	(10,230,173)			(10,964)	(10,219,209)
Issue of ordinary shares associated with Initial Public Offering (IPO) and follow-on offering	17,258,862	5,707,988	11,550,874
Reorganization of group structure		(24,347,208)	24,347,208
Transaction costs	(1,259,587)		(1,259,587)
Share based payments	42,757				42,757
Balance at end of period at Dec. 31, 2018	SFr 3,649,650	SFr 710,336	SFr 149,286,723	SFr (44,011)	SFr (146,303,398)

Consolidated Statement of Cash

Consolidated Statement of Cash Flows - CHF (SFr)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Cash flows from operating activities
Net loss	SFr (11,496,401)	SFr (24,409,474)	SFr (30,662,251)
Adjustments for:
Depreciation	72,713	122,784	97,600
Unrealized foreign currency exchange loss, net	211,214	776,165	99,091
Net interest expense	1,052,787	1,568,781	748,840
Loss on disposal of property and equipment	78,133	0	0
Share based payments	27,730	354,851	290,783
Transaction costs	520,125	1,026,766	0
Employee benefits	(37,491)	142,514	122,501
Revaluation gain derivative financial instruments	(1,350,071)	(3,372,186)	(291,048)
Income tax gain	162,177	(17,773)	(131,055)
Adjustments to reconcile profit (loss)	(10,759,084)	(23,807,572)	(29,725,539)
Changes in:
Other receivables	(18,390)	93,328	277,483
Prepayments	301,628	299,684	(771,551)
Trade and other payables	635,516	(637,177)	632,474
Accrued expenses	(3,391,834)	(224,028)	133,522
Net cash used in operating activities	(13,232,164)	(24,275,765)	(29,453,611)
Cash flows from investing activities
Purchase of property and equipment	0	(6,389)	(244,324)
Purchase of intangibles	(1,891,115)	(146,580)	0
Proceeds from disposals of property and equipment	68,160	0	0
Interest received	0	53,570	67,553
Net cash from / (used) in investing activities	(1,822,955)	(99,399)	(176,771)
Cash flows from financing activities
Share issuance costs	0	0	(1,862)
Proceeds from issue of loan with warrant	0	0	11,986,671
Proceeds from follow-on offering	17,447,499	13,039,066	0
Transaction costs	(2,006,577)	(1,548,281)	0
Repayment of loan	(9,272,328)	(2,087,076)	0
Interest paid	(435,993)	(1,182,369)	(546,170)
Net cash from financing activities	5,732,601	8,221,340	11,438,639
Net decrease in cash and cash equivalents	(9,322,518)	(16,153,824)	(18,191,743)
Cash and cash equivalents at beginning of the period	14,973,369	32,442,222	50,237,300
Net effect of currency translation on cash	(257,644)	(1,315,029)	396,665
Cash and cash equivalents at end of the period	SFr 5,393,207	SFr 14,973,369	SFr 32,442,222

Reporting entity

Reporting entity	12 Months Ended
	Dec. 31, 2018
Corporate Information and Statement of IFRS Compliance [Abstract]
Reporting entity	Reporting entity Auris Medical Holding AG (the “Company”) is a corporation ( Aktiengesellschaft ) organized in accordance with Swiss law and domiciled in Switzerland. The Company’s registered address is Bahnhofstrasse 21, 6300 Zug. These consolidated financial statements comprise the Company and its subsidiaries (together referred to as the “Group” and individually as “Group entities”). The Company is the ultimate parent of the following Group entities: • Auris Medical AG, Basel, Switzerland ( 100% ) with a nominal share capital of CHF 2,500,000 • Otolanum AG, Zug, Switzerland ( 100% ) with a nominal share capital of CHF 100,000 • Auris Medical Inc., Chicago, United States ( 100% ) with a nominal share capital of USD 15,000 • Auris Medical Ltd., Dublin, Ireland ( 100% ) with a nominal share capital of EUR 100 On April 22, 2014, the Company changed its name from Auris Medical AG to Auris Medical Holding AG. On May 21, 2014 the domicile of Auris Medical Holding AG was transferred from Basel to Zug. On March 13, 2018, the Company ("Auris OldCo") merged (the “Merger”) into Auris Medical NewCo Holding AG (“Auris NewCo”), a newly incorporated, wholly-owned Swiss subsidiary following shareholder approval at an extraordinary general meeting of shareholders held on March 12, 2018. Following the Merger, Auris NewCo, the surviving company, had a share capital of CHF 122,347.76 , divided into 6,117,388 common shares with a nominal value of CHF 0.02 each. Pursuant to the Merger, the Company’s shareholders received one common share with a nominal value of CHF 0.02 of Auris NewCo for every 10 of the Company's common shares held prior to the Merger, effectively resulting in a “reverse stock split” at a ratio of 10 -for-1. Auris NewCo changed its name to “Auris Medical Holding AG” following consummation of the Merger. On March 14, 2018 the common shares of Auris NewCo began trading on the Nasdaq Capital Market under the trading symbol “EARS.” The Group is primarily involved in the development of pharmaceutical products for the treatment of inner ear and vestibular disorders, in particular tinnitus and hearing loss. Its most advanced projects are in the late stage of clinical development.

Basis of preparation

Basis of preparation	12 Months Ended
	Dec. 31, 2018
Corporate Information and Statement of IFRS Compliance [Abstract]
Basis of preparation	Basis of preparation Statement of compliance These consolidated financial statements have been prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board (“IFRS”). These consolidated financial statements were approved by the Board of Directors of the Company on March 13, 2019. Basis of measurement The consolidated financial statements are prepared on the historical cost basis, except for the revaluation to fair value of certain financial liabilities. Historical cost is generally based on the fair value of the consideration given in exchange for goods and services. The principal accounting policies adopted are set out below. In addition, for financial reporting purposes, fair value measurements are categorized into Level 1, 2 or 3 based on the degree to which the inputs to the fair value measurements are observable and the significance of the inputs to the fair value measurement in its entirety, which are described as follows: • Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date • Level 2 inputs are inputs, other than quoted prices included within Level 1, that are observable for the asset or liability, either directly or indirectly; and • Level 3 inputs are unobservable inputs for the asset or liability. Functional and reporting currency These consolidated financial statements are presented in Swiss Francs (“CHF”), which is the Company’s functional (“functional currency”) and the Group’s reporting currency. Use of estimates and judgments The preparation of financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions of accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. Information about judgments made in applying accounting policies that have the most significant effects on the amounts recognized in the consolidated financial statements are described below. Income taxes As disclosed in Note 20 the Group has significant tax losses in Switzerland. These tax losses represent potential value to the Group to the extent that the Group is able to create taxable profits in Switzerland prior to expiry of such losses. Tax losses may be used within 7 years from the year the losses arose. The Group also has tax losses in the United States which may be used within 20 years of the end of the year in which losses arose, or for a shorter time period in accordance with prevailing state law. Other than a tax asset in the amount of CHF 305,206 , the Group has not recorded any deferred tax assets in relation to these tax losses. The key factors which have influenced management in arriving at this evaluation are the fact that the business is still in a development phase and the Group has not yet a history of making profits. Should management’s assessment of the likelihood of future taxable profits change, a deferred tax asset will be recorded. Income tax gain reflects the reassessment of deferred tax assets and liabilities booked in the 2018 fiscal year. Development expenditures The project stage forms the basis for the decision as to whether costs incurred for the Group’s development projects can be capitalized. For AM-101, AM-111 and AM-201 clinical development expenditures are not capitalized until the Group obtains regulatory approval (i.e. approval to commercially use the product), as this is considered to be essentially the first point in time where it becomes probable that future revenues can be generated. For the Group's intranasal betahistine program for the treatment of vertigo (AM-125), however, the development program of intranasal betahistine is primarily focused on the delivery route and formulation and not the drug itself (already an approved generic) and to demonstrate higher bioavailability through intranasal delivery. Given the nature of the development approach and the fact that there is an existing market in which oral betahistine for the treatment of vertigo has been approved, direct development expenditures have been capitalized. In addition, the Group has capitalized certain milestone payments with regard to license payments. As of each reporting date, the Group estimates the level of service performed by the vendors and the associated costs incurred for the services performed. As part of the process of preparing the Group’s financial statements, the Group is required to estimate its accrued expenses. This process involves reviewing contracts, identifying services that have been performed on the Group’s behalf and estimating the level of service performed and the associated cost incurred for the service when it has not yet been invoiced or otherwise notified of the actual cost. Employee benefits The Group maintains a pension plan for all employees in Switzerland through payments to a legally independent collective foundation. This pension plan qualifies under IFRS as defined benefit pension plan. The Group’s net obligation in respect of defined benefit plans is calculated by estimating the amount of future benefit that employees have earned in return for their service in the current and prior periods, discounting that amount and deducting the fair value of any plan assets. The Company makes relevant actuarial assumptions with regard to the discount rate, future salary increases and life expectancy. Considering reorganization / Merger The Merger is not a business combination and is accounted for as a reorganization. Therefore, the consolidated financial statements of the Company are a continuation of the financial information of Auris Old Co except that the consolidated financial statements reflect a classification between share capital and share premium in order to reflect the share capital of Auris NewCo. For the periods prior to the Merger, in calculating loss per share, the weighted average number of shares outstanding is calculated based on the number of weighted average shares issued by Auris Old Co, adjusted for the reverse stock split ratio of 10-for-1 resulting from the Merger.

Significant accounting policies

Significant accounting policies	12 Months Ended
	Dec. 31, 2018
Corporate Information and Statement of IFRS Compliance [Abstract]
Significant accounting policies	Significant accounting policies The accounting policies set out below have been applied consistently to all periods presented in these consolidated financial statements, unless otherwise indicated. Basis of consolidation Subsidiaries Subsidiaries are entities controlled by the Group. The Group controls an entity when it is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. The financial statements of subsidiaries are included in the consolidated financial statements from the date on which control commences until the date on which control ceases. Transactions eliminated on consolidation All inter-company balances, transactions and unrealized gains on transactions have been eliminated in consolidation. Unrealized losses are also eliminated unless the transaction provides evidence of an impairment of the asset transferred. Segment reporting A segment is a distinguishable component of the Group that engages in business activities from which it may earn revenues and incur expenses, including revenues and expenses that relate to transactions with any of the Group’s other components. The Chief Executive Officer is determined to be the Group’s Chief Operating Decision Maker (“CODM”). The CODM assesses the performance and allocates the resources of the Group as a whole, as all of the Group’s activities are focusing on the development of pharmaceutical products for the treatment of inner ear and vestibular disorders. Financial information is only available for the Group as a whole. Therefore, management considers there is only one operating segment under the requirements of IFRS 8, Operating Segments. Foreign currency Foreign currency transactions Items included in the financial statements of Group entities are measured using the currency of the primary economic environment in which the entity operates. Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized in profit or loss. Non-monetary items that are measured based on historical cost in a foreign currency are not re-translated. Foreign operations Assets and liabilities of Group entities whose functional currency is other than CHF are included in the consolidation by translating the assets and liabilities into the reporting currency at the exchange rates applicable at the end of the reporting period. Income and expenses are translated at average exchange rates (unless this average is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, in which case income and expenses are translated at the dates of the transaction). These foreign currency translation differences are recognized in Other Comprehensive Loss and presented in the foreign currency translation reserve in equity. When a foreign operation is disposed of such that control is lost, the cumulative amount in the translation reserve related to that foreign operation is reclassified to profit or loss as part of the gain or loss on disposal. Closing rates for the most significant foreign currencies relative to CHF: Currency Geographical area Reporting entities December 31, 2018 December 31, 2017 December 31, 2016 CHF Swiss Franc Switzerland 3 1.0000 1.0000 1.0000 USD Dollar United States 1 0.9827 0.9725 1.0196 EUR Europe Europe 1 1.1283 1.1713 1.0723 Average exchange rates for the year for the most significant foreign currencies relative to CHF: Currency Geographical area Reporting entities 2018 2017 2016 CHF Swiss Franc Switzerland 3 1.0000 1.0000 1.0000 USD Dollar United States 1 0.9768 0.9849 0.9855 EUR Europe Europe 1 1.1573 1.1116 1.0901 Property and equipment Property and equipment is measured at historical costs less accumulated depreciation and any accumulated impairment losses. Historical costs include expenditures that are directly attributable to the acquisition of the items. When parts of an item of tangible assets have different useful lives, they are accounted for as separate tangible asset items (major components). Depreciation is calculated on a straight-line basis over the expected useful life of the individual asset or the shorter remaining lease term for leasehold improvements. The applicable estimated useful lives are as follows: Production equipment 5 years Office furniture and electronic data processing equipment (“EDP”) 3 years Leasehold improvements 5 years Subsequent costs are included in the asset’s carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Group and the cost of the item can be measured reliably. The carrying amount of the replaced part is derecognized. All other repairs and maintenance are charged to profit or loss during the financial period in which they are incurred. Depreciation methods, useful lives and residual values are reviewed at each reporting date and adjusted if appropriate. When an asset is reviewed for impairment, the asset’s carrying amount may be written down immediately to its recoverable amount, provided the asset’s carrying amount is greater than its estimated recoverable amount. Management assesses the recoverable amount by assessing the higher of its fair value less costs to sell or its value in use. Cost and accumulated depreciation related to assets retired or otherwise disposed are removed from the accounts at the time of retirement or disposal and any resulting gain or loss is included in profit or loss in the period of disposition. Intangible assets Research and development Expenditures on the Group’s research programs are not capitalized, they are expensed when incurred. Expenditures on the Group’s development programs are generally not capitalized except if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Group intends to and has sufficient resources to complete development and to use or sell the asset. For the development projects of the Group, these criteria are generally only met when regulatory approval for commercialization is obtained. This has been the general assessment for AM-101, AM-111 and AM-201. For the AM-125 program for the treatment of Vertigo it is the Group assessment that the criteria mention above is met and therefore direct development expenditures have been capitalized for AM-125 in 2018. Intellectual property-related costs for patents are part of the expenditure for research and development projects. Therefore, registration costs for patents are expensed when incurred as long as the research and development project concerned does not meet the criteria for capitalization. Licenses, intellectual property and data rights Intellectual property rights that are acquired by the Group are capitalized as intangible assets if they are controlled by the Group, are separately identifiable and are expected to generate future economic benefits, even if uncertainty exists as to whether the research and development will ultimately result in a marketable product. Consequently, upfront and milestone payments to third parties for the exclusive use of pharmaceutical compounds in specified areas of treatment are recognized as intangible assets. Measurement Intangible assets acquired that have finite useful lives are measured at cost less accumulated amortization and any accumulated impairment losses. Subsequent expenditure Subsequent expenditure is capitalized only when it increases the future economic benefits embodied in the specific asset to which it relates. All other expenditure, including expenditure on internally generated goodwill and brands, is recognized in profit or loss as incurred. Amortization All licenses of the Group have finite lives. Amortization will commence once the Group’s intangible assets are available for use which will be the case after regulatory approvals are obtained and the related products are available for use. Amortization of licenses is calculated on a straight line basis over the period of the expected benefit or until the license expires, whichever is shorter. The estimated useful life is 10 years or the remaining term of patent protection. The Group assesses at each statement of financial position date whether intangible assets which are not yet ready for use are impaired. Impairment of non-financial assets Property and equipment and intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. For the purpose of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash flows (cash-generating units). An impairment loss is recognized as the amount by which the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s fair value less costs to sell or value in use. Impairment losses are recognized in profit or loss. Assets that were previously impaired are reviewed for possible reversal of the impairment at each reporting date. Any increase in the carrying amount of an asset will be based on the depreciated historical costs had the initial impairment not been recognized. Financial instruments The Group classifies its financial assets in the following categories: loans and receivables based on the expected loss model. The classification depends on the nature and purpose of the financial assets and is determined at the time of initial recognition. The date of initial application (i.e. the date on which the Company has assessed its existing financial assets and financial liabilities in terms of IFRS 9 requirements) is January 1, 2018. Accordingly, the Company has applied the requirements of IFRS 9 to instruments that continue to be recognized at January 1, 2018 whereas for the year ended December 31, 2017 IAS 39 was applied. Recognition and derecognition of non-derivative financial assets and liabilities The Group initially recognizes loans and receivables and debt securities issued on the date when they are originated. All other financial assets and financial liabilities are initially recognized on the trade date. The Group derecognizes a financial asset when the contractual rights to the cash flows from the asset expire, or it transfers the rights to receive the contractual cash flows in a transaction in which substantially all of the risks and rewards of ownership of the financial asset are transferred, or it neither transfers nor retains substantially all of the risks and rewards of ownership and does not retain control over the transferred asset. Any interest in such derecognized financial assets that is created or retained by the Group is recognized as a separate asset or liability. The Group derecognizes a financial liability when its contractual obligations are discharged, cancelled, or expired. Financial assets and financial liabilities are offset and the net amount presented in the statement of financial position when, and only when, the Group has a legal right to offset the amounts and intends either to settle them on a net basis or to realize the asset and settle the liability simultaneously. Non-derivative financial assets and liabilities—measurement Loans and receivable These are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. Loans and receivables are initially recognized at fair value plus any directly attributable transaction costs. Subsequent to initial recognition, they are measured at amortized cost using the effective interest method, less expected losses. Cash and cash equivalents The Group considers all short-term, highly liquid investments that are readily convertible into known amounts of cash and which are subject to an insignificant risk of changes in value with original maturities of three months or less at the date of the purchase to be cash equivalents. Non-derivative financial liabilities—measurement Non-derivative financial liabilities are initially recognized at fair value less any directly attributable transaction costs. Subsequent to initial recognition, these liabilities are measured at amortized cost using the effective interest method. Share capital All shares of the Company are registered shares and classified as part of shareholders’ equity. Incremental costs directly attributable to the issue of the Company’s shares, net of any tax effects, are recognized as a deduction from equity. The warrants are classified as a financial liability at fair value through profit or loss and the cost allocated to the liability component will be immediately expensed to the income statement. The Company has not paid any dividends since its inception and does not anticipate paying dividends in the foreseeable future. Repurchase and reissue of ordinary shares (treasury shares) When shares recognized as equity are repurchased, the amount of the consideration paid, which includes directly attributable costs, net of any tax effects, is recognized as a deduction from equity. Repurchased shares are classified as treasury shares and are presented in the treasury share reserve. When treasury shares are sold or reissued subsequently, the amount received is recognized as an increase in equity and the resulting surplus or deficit (calculated as the difference between initial cost and fair value) on the transaction is presented within share premium. Impairment of non-derivative financial assets Financial assets are assessed at each reporting date to determine whether there is objective evidence of impairment. Objective evidence that financial assets are impaired includes: • default or delinquency by a debtor; • indications that a debtor or issuer will enter bankruptcy; • adverse changes in the payment status of borrowers or issuers; • the disappearance of an active market for a security; or • observable data indicating that there is measurable decrease in expected cash flows from a group of financial assets. Financial assets measured at amortized cost The Group considers evidence of impairment for these assets at an individual asset level. An impairment loss is calculated as the difference between an asset’s carrying amount and the present value of the estimated future cash flows discounted at the asset’s original effective interest rate. Losses are recognized in profit or loss and reflected in an allowance account. When the Group considers that there are no realistic prospects of recovery of the asset, the relevant amounts are written off. If the amount of impairment loss subsequently decreases and the decrease can be related objectively to an event occurring after the impairment was recognized, then the previously recognized impairment loss is reversed through profit or loss. Derivative Financial Instruments Derivative financial instrument (asset) is accounted as the cost to obtain the rights from a third party to issue shares under the purchase agreement and changes in fair value are shown as profit or loss. The fair value calculation of the derivative financial instrument (asset) is adjusted on the utilization of the asset based on total dollar amount of the purchase agreement. Derivative financial instruments (liabilities) are accounted at fair value and changes in fair value are shown as profit or loss. The fair value calculation of the derivative financial instruments is based on the Black-Scholes option pricing model. Assumptions are made for volatility and the risk free rate in order to estimate the fair value of the instrument. Transaction cost related to derivative financial instruments are recorded through profit and loss. Income tax Income tax expense comprises current and deferred tax. It is recognized in profit or loss except to the extent that it relates to a business combination, or items recognized directly in equity or in Other Comprehensive Income. Current tax Current tax comprises the expected tax payable or receivable on the taxable income or loss for the year and any adjustment to tax payable or receivable in respect of previous years. It is measured using tax rates enacted or substantively enacted at the reporting date. Deferred tax Deferred income tax is recognized, using the balance sheet liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the consolidated financial statements. Deferred tax is not recognized for: • temporary differences on the initial recognition of assets or liabilities in a transaction that is not a business combination and that affects neither accounting nor taxable profit or loss; • temporary differences related to investments in subsidiaries to the extent that the Group is able to control the timing of the reversal of the temporary differences and it is probable that they will not reverse in the foreseeable future; and • taxable temporary differences arising on the initial recognition of goodwill. Deferred income tax is determined using tax rates and laws that have been enacted or substantively enacted by the reporting date and are expected to apply when the related deferred income tax asset is realized or the deferred income tax liability is settled. Deferred income tax assets are recognized to the extent that it is probable that future taxable profit will be available against which the temporary differences can be utilized. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realized. Deferred tax assets and liabilities are offset when there is a legally enforceable right to set off tax assets against tax liabilities and when they relate to income taxes levied by the same taxation authority and the Group intends to settle its tax assets and liabilities on a net basis. Employee benefits The Group maintains a pension plan for all employees in Switzerland through payments to a legally independent collective foundation. This pension plan qualifies under IFRS as defined benefit pension plan. There are no pension plans for the subsidiaries in Ireland and the United States. The Group’s net obligation in respect of defined benefit plans is calculated by estimating the amount of future benefit that employees have earned in return for their service in the current and prior periods, discounting that amount and deducting the fair value of any plan assets. The recognized asset is limited to the present value of economic benefits available in the form of any future refunds from the plan or reductions in future contributions to the plan. In order to calculate the present value of economic benefits, consideration is given to any minimum funding requirements. Remeasurements of the net defined benefit liability, which comprise actuarial gains and losses, the return on plan assets (excluding interest) and the effect of the asset ceiling (if any, excluding interest), are recognized immediately in Other Comprehensive Income. Past service costs, including curtailment gains or losses, are recognized immediately in general and administrative expenses within the operating results. Settlement gains or losses are recognized in general and administrative expenses within the operating results. The Group determines the net interest expense (income) on the net defined benefit liability (asset) for the period by applying the discount rate used to measure the defined benefit obligation at the beginning of the annual period or in case of any significant events between measurement dates to the then-net defined benefit liability (asset), taking into account any changes in the net defined benefit liability (asset) during the period as a result of contributions and benefit payments. Net interest expense and other expenses related to defined benefit plans are recognized in profit or loss. Share-based compensation The Company maintains various share-based payment plans in the form of stock option plans for its employees, members of the Board of Directors as well as key service providers. Stock options are granted at the Board’s discretion without any contractual or recurring obligations. The share-based compensation plans qualify as equity settled plans. The grant-date fair value of share-based payment awards granted to employees is recognized as an expense, with a corresponding increase in equity, over the period that the employees become unconditionally entitled to the awards. The vesting of share options is conditional on the employee completing a period of service of three and four years respectively, from the grant date, in accordance with Stock Option Plans A and C. Under the Auris Medical Holding AG Long Term Equity Incentive Plan (the “Equity Incentive Plan” or “EIP”), 50% of granted share options granted to employees vest after a period of service of two years from the grant date and the remaining 50% vest after a period of service of three years from the grant date. Share options granted to members of the Board of Directors in 2018, 2017 and in 2016 vest after a period of one year after the grant date. Stock Option Plan B was created to provide shares for share based compensation plans; it was used in the years 2008, 2009 and 2014 and was abolished in 2015. The amount recognized as an expense is adjusted to reflect the number of awards for which the related service and non-market performance conditions are expected to be met, such that the amount ultimately recognized as an expense is based on the number of awards that meet the related service and non-market performance conditions at the vesting date. Share-based payments that are not subject to any further conditions are expensed immediately at grant date. In the year the options are exercised the proceeds received net of any directly attributable transaction costs are credited to share capital (nominal value) and share premium. Valuation of share options Following the completion of the Company's initial public offering, option pricing and values are determined based on the Black Scholes option pricing model and assumptions are made for inputs such as volatility of the Company's stock and the risk free rate. Provisions Provisions are recognized when the Group has a present obligation (legal or constructive) as a result of a past event, where it is more likely than not that an outflow of resources will be required to settle the obligation, and where a reliable estimate can be made of the amount of the obligation. Provisions are not recognized for future operating losses. Provisions are measured at the present value of the expenditures expected to be required to settle the obligation using a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability. Leases Leases in which a significant portion of the risks and rewards of ownership are retained by the lessor are classified as operating leases. Payments made under operating leases (net of any incentives received from the lessor) are charged to profit or loss on a straight-line basis over the period of the lease. Earnings/(loss) per share Basic earnings/(loss) per share are calculated by dividing the net profit/(loss) attributable to owners of the Company by the weighted average number of shares outstanding during the period. Diluted earnings/(loss) per share are calculated by dividing the net profit/(loss) attributable to the owners of the Company by the weighted average number of shares outstanding during the period adjusted for the conversion of all dilutive potential ordinary shares.

New standards, amendments and i

New standards, amendments and interpretations adopted by the Group	12 Months Ended
	Dec. 31, 2018
Accounting Policies, Accounting Estimates And Errors [Abstract]
New standards, amendments and interpretations adopted by the Group	New standards, amendments and interpretations adopted by the Group In the current year, the following revised standards have been adopted in these financial statements. Adoption has not had a material impact on the amounts reported in these financial statements but may impact the accounting for future transactions and arrangements. IFRS 9 Financial instruments IFRS 15 Revenue from Contracts with Customers and the related clarifications IFRS 2 - Amendment Classification and Measurement of Share-based Payment Transaction IFRIC 22 Foreign Currency Transactions and Advance Consideration A number of new standards, amendments to standards and interpretations are effective for annual periods beginning after January 1, 2019 , and have not been applied in preparing these consolidated financial statements. Standard/Interpretation Impact Effective date Planned application by the Group New standards, interpretations or amendments IFRS 16 Leases 1) January 1, 2019 FY 2019 IFRIC 23 Uncertainty over Income Tax Positions 2) January 1, 2019 FY 2019 IFRS 9 Amendments to IFRS 9, Prepayment Features with negative Compensation 2) January 1, 2019 FY 2019 IAS 28 Amendments to IAS 28, Long-term Interests in Associates and Joint Ventures 2) January 1, 2019 FY 2019 IAS 19 Amendments to IAS 19, Plan Amendment, Curtailment or Settlement 2) January 1, 2019 FY 2019 Various Annual Improvements to IFRS Standards 2015-2017 Cycle. 2) January 1, 2019 FY 2019 Various Amendments to References to Conceptual Framework in IFRS Standards. 2) January 1, 2020 FY 2020 IFRS 17 Insurance contracts 2) January 1, 2021 FY 2021 1) IFRS 16, Leases The new standard eliminates the current classification model for lessee's lease contracts as either operating or finance leases and, instead, introduces a single lessee accounting model requiring lessees to recognize right-of-use assets and lease liabilities for leases with a term of more than twelve months. This brings the previous off-balance leases on the balance sheet in a manner largely comparable to current finance lease accounting. A lessee can choose to apply the standard using either a full retrospective or a modified retrospective approach. Adoption of IFRS 16 will result in the Group recognizing right of use assets and lease liabilities for all contracts that are, or contain, a lease. For leases currently classified as operating leases, under current accounting requirements the Group does not recognize related assets or liabilities, and instead spreads the lease payments on a straight-line basis over the lease term, disclosing in its annual financial statements the operating lease commitment. The Group current leasing arrangements relating to office space are for 6 months and will not be capitalized under IFRS 16. 2) No material impact on the Group is expected from these standards and amendments issued but not effective.

Financial instruments and risk

Financial instruments and risk management	12 Months Ended
	Dec. 31, 2018
Financial Instruments [Abstract]
Financial instruments and risk management	Financial instruments and risk management The following table shows the carrying amounts of financial assets and financial liabilities: Financial assets December 31, 2018 December 31, 2017 Cash and cash equivalents 5,393,207 14,973,369 Loans and receivables Other receivables 80,040 79,840 Total financial assets 5,473,247 15,053,209 Financial liabilities At amortized cost Trade and other payables 1,836,335 1,200,820 Accrued expenses 1,290,879 4,395,609 Loan 1,435,400 10,126,406 At fair value through profit and loss Derivative financial instruments 675,328 1,836,763 Total financial liabilities 5,237,942 17,559,598 Fair values The carrying amount of cash and cash equivalents, other receivables, trade and other payables and accrued expenses is a reasonable approximation of their fair value due to the short term nature of these instruments. In respect of the Company’s loan which has floating rates of interest, the fair value approximates carrying value. Financial risk factors The Group’s activities expose it to a variety of financial risks: market risk, credit risk, interest rate and liquidity risk. The Group’s overall risk management program focuses on the unpredictability of financial markets and seeks to minimize potential adverse effects on the Group’s financial performance. Management identifies, evaluates and controls financial risks. No financial derivatives have been used in 2018 and 2017 to hedge risk exposures. The Group invests its available cash in instruments with the main objectives of preserving principal, meeting liquidity needs and minimizing foreign exchange risks. The Group allocates its liquid assets to first tier Swiss or international banks. Liquidity risk The Group’s principal source of liquidity is its cash reserves which are mainly obtained through the issuance of new shares. The Group has succeeded in raising capital to fund its development activities to date and has raised funds that will allow it to meet short term development expenditures. The Company will require regular capital injections to continue its development work, which may be dependent on meeting development milestones, technical results and/or commercial success. Management monitors rolling forecasts of the Group’s liquidity requirements to ensure it has sufficient cash to meet operational needs. The ability of the Group to maintain adequate cash reserves to sustain its activities in the medium term is highly dependent on the Group’s ability to raise further funds. Consequently, the Group is exposed to continued liquidity risk. The table below analysis the remaining contractual maturities of financial liabilities, including estimated interest payments as of December 31, 2018 and 2017 . The amounts disclosed in the table are the undiscounted cash flows: Carrying amount Less than 3 months Between 3 months and 2 years 2 years and later Total December 31, 2018 Trade and other payables 1,836,335 1,836,335 — — 1,836,335 Accrued expenses 1,290,879 1,290,879 — — 1,290,879 Loan and borrowings 1,435,400 1,435,400 — — 1,435,400 Derivative financial instruments 675,328 — 215,572 459,756 675,328 Total 5,237,942 4,562,614 215,572 459,756 5,237,942 Carrying amount Less than 3 months Between 3 months and 2 years 2 years and later Total December 31, 2017 Trade and other payables 1,200,820 1,200,820 — — 1,200,820 Accrued expenses 4,395,609 4,395,609 — — 4,395,609 Loan and borrowings 10,126,406 1,349,531 9,446,716 1,166,225 11,962,472 Derivative financial instruments 1,836,763 — — 1,836,763 1,836,763 Total 17,559,598 6,945,960 9,446,716 3,002,988 19,395,664 Fair value measurement Financial Fair values as at Fair value Valuation technique(s) and key input(s) December 31, December 31, Derivative financial liabilities Liability Liability Level 2 Black-Scholes option pricing model Derivative financial asset Asset Asset Level 3 The fair value is equal to the price paid to the counter party for obtaining the right under the purchase agreement. Subsequent, the fair value is adjusted proportionally for the part of the right consumed. Non-cash changes 01.01.2018 Financing 1) Fair Other 2) 31.12.2018 Derivative 1,836,763 188,636 (1,350,071 ) — 675,328 Loans 10,126,406 (9,272,328 ) — 581,322 1,435,400 Total 11,963,169 (9,083,692 ) (1,350,071 ) 581,322 2,110,728 Non-cash changes 01.01.2017 Financing 1) Fair Other 2) 31.12.2017 Derivative 117,132 5,091,817 (3,372,186 ) — 1,836,763 Loans 12,364,204 (2,087,076 ) — (150,722 ) 10,126,406 Total 12,481,336 3,004,741 (3,372,186 ) (150,722 ) 11,963,169 1) The financing cash flows are from loan repayment and from issuance of new derivative 2) IRR-Correction and FX-Difference Credit risk Credit risk is managed on a Group basis. Credit risk arises from cash and cash equivalents and deposits with banks, as well as from other receivables. The Company’s policy is to invest funds in low risk investments including interest bearing deposits. Other receivables were current as of December 31, 2018 and December 31, 2017 , not impaired and included only well-known counterparties. The Group has been holding cash and cash equivalents in the Group’s principal operating currencies (CHF, USD and EUR) with international banks of high credit rating. The Group’s maximum exposure to credit risk is represented by the carrying amount of each financial asset in the consolidated statement of financial position: December 31, 2018 December 31, 2017 Financial assets Cash and cash equivalents 5,393,207 14,973,369 Other receivables 80,040 79,840 Total 5,473,247 15,053,209 As of December 31, 2018 and December 31, 2017 other receivables consisted of other non-current receivables from third party and deposits for rent. Market risk Currency risk The Group operates internationally and is exposed to foreign exchange risk arising from various exposures, primarily with respect to US Dollar and Euro. Foreign exchange risk arises from future commercial transactions, recognized assets and liabilities and net investments in foreign operations. The summary of quantitative data about the exposure of the Group’s financial assets and liabilities to currency risk was as follows: 2018 2017 in CHF USD EUR USD EUR Cash and cash equivalents 3,618,778 208,507 13,901,698 116,942 Trade and other payables (1,646,910 ) (76,184 ) (365,999 ) (426,050 ) Accrued expenses (82,847 ) (370,145 ) (1,750,752 ) (1,692,946 ) Loan and borrowings (1,435,400 ) — (10,126,406 ) — Derivative financial instruments (675,328 ) — (1,836,763 ) — Net statement of financial position exposure -asset/(liability) (221,707 ) (237,822 ) (178,222 ) (2,002,054 ) As of December 31, 2018 , a 5% increase or decrease in the USD/CHF exchange rate with all other variables held constant would have resulted in a CHF 10,886 ( 2017 : CHF 8,662 ) increase or decrease in the net result. Also, a 5% increase or decrease in the EUR/CHF exchange rate with all other variables held constant would have resulted in a CHF 13,413 ( 2017 : CHF 117,320 ) increase or decrease in the net result. The Company has subsidiaries in the United States and Ireland, whose net assets are exposed to foreign currency translation risk. Due to the small size of the subsidiaries the translation risk is not significant. Interest rate risk On July 19, 2016, the Company entered into a Loan and Security Agreement for a secured term loan facility of up to $ 20.0 million with Hercules Capital, Inc. as administrative agent (“Hercules”) and the lenders party thereto. An initial tranche of $ 12.5 million was drawn on July 19, 2016, concurrently with the execution of the loan agreement. The loan matures on January 2, 2020 and bears interest at a minimum rate of 9.55% per annum, and is subject to the variability of the prime interest rate. The Company’s exposure to interest rates on financial assets and financial liabilities is resulting from loan and cash at banks. As of December 31, 2018 an increase or decrease in interest rates on financial obligations by 50 basis points with all other variables held constant would have resulted in a CHF 3,721 ( 2017 : 62,500 ) increase or decrease in the net result. Capital risk management The Company and its subsidiaries are subject to capital maintenance requirements under local law in the country in which it operates. To ensure that statutory capital requirements are met, the Company monitors capital, at the entity level, on an interim basis as well as annually. From time to time the Company may take appropriate measures or propose capital increases to ensure the necessary capital remains intact.

Segment information

Segment information	12 Months Ended
	Dec. 31, 2018
Operating Segments [Abstract]
Segment information	Segment information Geographical information The Group’s non-current assets by the Company’s country of domicile were as follows: December 31, 2018 December 31, 2017 Switzerland 3,812,001 1,958,709 Total 3,812,001 1,958,709 Non-current assets exclude financial instruments.

Property and equipment

Property and equipment	12 Months Ended
	Dec. 31, 2018
Property, plant and equipment [abstract]
Property and equipment	Property and Equipment Production equipment Office furniture and EDP Leasehold improvements Total At cost As of January 1, 2017 283,499 233,706 236,462 753,667 Additions 6,389 — — 6,389 As of December 31, 2017 289,888 233,706 236,462 760,056 Additions — — — — Disposals — — (236,462 ) (236,462 ) As of December 31, 2018 289,888 233,706 — 523,594 Accumulated depreciation As of January 1, 2017 (184,329 ) (183,710 ) (16,334 ) (384,373 ) Charge for the year (53,594 ) (21,918 ) (47,272 ) (122,784 ) As of December 31, 2017 (237,923 ) (205,628 ) (63,606 ) (507,157 ) Charge for the year (32,485 ) (13,663 ) (26,565 ) (72,713 ) Disposals — — 90,171 90,171 As of December 31, 2018 (270,408 ) (219,291 ) — (489,699 ) Net book value As of December 31, 2017 51,965 28,078 172,856 252,899 As of December 31, 2018 19,480 14,415 — 33,895 As of December 31, 2018 , and 2017 no items of property and equipment were pledged. Refer to note 24 for security provided to Hercules Capital, Inc. under the Loan and Security Agreement.

Intangible assets

Intangible assets	12 Months Ended
	Dec. 31, 2018
Intangible Assets [Abstract]
Disclosure of intangible assets [text block]	Intangible assets Licenses IP & Data rights Internally generated Total At cost As of January 1, 2017 1,482,520 — — 1,482,520 As of December 31, 2017 1,482,520 146,580 — 1,629,100 As of December 31, 2018 1,482,520 193,989 1,858,731 3,535,240 Accumulated amortization and impairment losses As of December 31, 2017 — — — — As of December 31, 2018 — — — — Net book value As of December 31, 2017 1,482,520 146,580 — 1,629,100 As of December 31, 2018 1,482,520 193,989 1,858,731 3,535,240 Intangible assets comprise upfront and milestone payments related to licenses. In 2013 a milestone of CHF 1,125,000 related to the AM-111 program was recorded. Amortization will commence once the intangible assets are available for use, which will be the case after regulatory approvals are obtained and the related products are available for use. On February 2, 2017, the Company entered into an asset purchase agreement with Otifex Therapeutics Pty Ltd (“Otifex”), pursuant to which the Company agreed to purchase and Otifex has agreed to sell to the Company certain pre-clinical and clinical assets related to a formulation for the intranasal application of Betahistine, which the Company refers to as AM-125, as well as intellectual property rights. The Otifex transaction closed in July 2017 and the Company recorded CHF 146,580 as intangibles related to this transaction. On December 6, 2018, in two related transactions the Company acquired an Orphan Drug Designation for betahistine in the treatment of obesity associated with Prader-Willi syndrome (PWS) and signed a binding letter of intent to in-license exclusive rights to two U.S. Patents relating to the use of betahistine for the treatment of depression and attention-deficit / hyperactivity disorder (ADHD), respectively. The Company recorded CHF 47,409 related to these transactions. During the year ended December 31, 2018 the Company recorded intangibles related to direct development expenditure of its AM-125 program for an amount of CHF 1,858,731 . No amortization or impairment was recorded in 2018 and 2017 .

Other receivables

Other receivables	12 Months Ended
	Dec. 31, 2018
Trade and other receivables [abstract]
Other receivables	Other receivables December 31, 2018 December 31, 2017 Value added tax receivable 96,853 63,452 Withholding tax receivable 18,526 18,115 Deposit credit cards 80,040 79,840 Other 124,955 79,874 Total other receivables 320,374 241,281 Other receivables were not considered impaired in the years under review.

Prepayments

Prepayments	12 Months Ended
	Dec. 31, 2018
Subclassifications of assets, liabilities and equities [abstract]
Prepayments	Prepayments December 31, 2018 December 31, 2017 Advance payments to supplier 212,207 442,828 Insurance 139,076 200,246 Other — 9,839 Total prepayments 351,283 652,913

Cash and cash equivalents

Cash and cash equivalents	12 Months Ended
	Dec. 31, 2018
Subclassifications of assets, liabilities and equities [abstract]
Cash and cash equivalents	Cash and cash equivalents December 31, 2018 December 31, 2017 Cash in bank accounts 5,392,599 14,972,761 Cash on hand 608 608 Total cash and cash equivalents 5,393,207 14,973,369

Capital and reserves

Capital and reserves	12 Months Ended
	Dec. 31, 2018
Share capital, reserves and other equity interest [Abstract]
Capital and reserves	Capital and reserves Share capital The issued share capital of the Company at December 31 consisted of: December 31, 2018 December 31, 2017 Number CHF Number CHF Common shares with a nominal value of CHF 0.40 each — — 48,373,890 19,349,556 Common shares with a nominal value of CHF 0.02 each 35,516,785 710,336 — — Total 35,516,785 710,336 48,373,890 19,349,556 Common Shares (Number) 2018 2017 As of January 1 48,373,890 34,329,704 Common shares issued for the follow-on offering with a 12,800,000 14,044,186 nominal value of CHF 0.40 each Adjustment during the Merger: Issuance of Auris NewCo Shares 6,117,388 — Cancellation of Auris OldCo Shares (61,173,890 ) — Common shares issued for capital increase with a nominal value of CHF 0.02 each 29,399,397 — Total, as of December 31 35,516,785 48,373,890 All shares have a nominal value of CHF 0.02 and are fully paid in. As of December 31, 2018, the nominal value of the 35,516,785 issued shares amounted to CHF 710,335.70 (as of December 31, 2017, the nominal value of 48,373,890 issued shares was CHF 0.40 and amounted to CHF 19,349,556.00 ). On November 30, 2018, the Company entered into a sales agreement (the “A.G.P. Sales Agreement”) with A.G.P./Alliance Global Partners (“A.G.P.”). Pursuant to the terms of the A.G.P. Sales Agreement, the Company may offer and sell its common shares, from time to time through A.G.P. by any method deemed to be an “at-the-market” offering as defined in Rule 415(a)(4) promulgated under the Securities Act. Pursuant to the A.G.P. Sales Agreement, the Company may sell common shares up to a maximum aggregate offering price of $25.0 million . As of December 31, 2018 the Company had sold 616,740 of its common shares for an aggregate offering price of CHF 350,486 . As of the date of these consolidated financial statements, the Company has sold 2,595,814 of its common shares for an aggregate offering price of $1.3 million pursuant to the A.G.P. Sales Agreement. On November 27, 2018 and December 11, 2018, the Company entered into purchase agreements with FiveT Capital AG, providing for the issuance and sale by us of an aggregate of 3,315,000 of its common shares for an aggregate purchase price of CHF 1.6 million in two separate registered direct offerings. On July 17, 2018 the Company completed a public offering of 17,948,717 common shares with a nominal value of CHF 0.02 each, Series A warrants each entitling its holder to purchase 0.35 of a common share and for an aggregate of 6,282,051 common shares, and Series B warrants entitling its holder to purchase 0.25 of a common share for an aggregate of 4,487,178 common shares (the “July 2018 Registered Offering”). The exercise price for both series Warrants is CHF 0.39 per common share. The net proceeds to the Company from the July 2018 Registered Offering were approximately CHF 6.2 million , after deducting underwriting discounts and other offering expenses payable by us. The Company had transaction costs amounting to CHF 851,692 . The transactions costs were recorded as CHF 742,833 in equity for the issuance of the common shares and CHF 108,809 to finance expense in the statement of profit or loss and comprehensive loss for the issuance of the warrants. On May 2, 2018 the Company entered into a purchase agreement (the "2018 Commitment Purchase Agreement") and a registration rights agreement (the "2018 Registration Rights Agreement") with Lincoln Park Capital LLC ("LPC"). Pursuant to the 2018 Commitment Purchase Agreement, LPC agreed to purchase common shares for up to $10,000,000 over the 30 -month term of the 2018 Commitment Purchase Agreement. As of the date of these consolidated financial statements, the Company has issued an aggregate of 1,750,000 common shares for aggregate proceeds of CHF 1.0 million to LPC under the 2018 Commitment Purchase Agreement. The 2018 Commitment Purchase Agreement replaces the 2017 Commitment Purchase Agreement (as defined below), which was terminated as a result of the Merger. Under the 2017 Commitment Purchase Agreement, LPC agreed to subscribe for up to $13,500,000 common shares and prior to its termination, the Company had issued an aggregate of 2,600,000 common shares for aggregate proceeds of CHF 1.7 million to LPC under the 2017 Commitment Purchase Agreement. The Company had transaction costs amounting to CHF 349,907 . The payment of CHF 252,351 was recorded as a derivative financial instrument and classified as a non-current asset and CHF 97,556 to finance expense in the statement of profit or loss and comprehensive loss. On January 30, 2018, the Company completed a public offering of 12,499,999 common shares with a nominal value of CHF 0.40 each and concurrent offering of 7,499,999 warrants, each warrant entitling its holder to purchase one common share (the “January 2018 Registered Offering”). The net proceeds to the Company from the January 2018 Registered Offering were approximately CHF 4.5 million , after deducting placement agent fees and other estimated offering expenses payable by the Company. As of March 13, 2018, following the consummation of the Merger, the outstanding warrants issued in the January 2018 Registered Offering were exercisable for up to 750,002 common shares (assuming the Company rounds up fractional common shares to the next whole common share) at an exercise price of $5.00 per common share. The Company had transaction costs amounting to CHF 654,985 . The transaction costs were recorded as CHF 341,226 in equity for the issuance of the common shares and CHF 313,760 to finance expense in the statement of profit or loss and comprehensive loss for the issuance of the warrants. On October 10, 2017, the Company entered into a purchase agreement (the “2017 Commitment Purchase Agreement”) and a Registration Rights Agreement (the “2017 Registration Rights Agreement”) with LPC. Pursuant to the 2017 Commitment Purchase Agreement, LPC has agreed to subscribe for up to $13,500,000 of the Company's common shares over the 30 -month term of the 2017 Commitment Purchase Agreement. Regular purchases may be made from time to time under the 2017 Commitment Purchase Agreement subject to certain amount limitations. As of December 31, 2017, the Company has issued an aggregate of 2,300,000 common shares for aggregate proceeds of CHF 1,594,611 ( $1,630,415 ) to LPC pursuant to the 2017 Commitment Purchase Agreement. The related transaction cost of CHF 25,701 were recorded in equity. The transaction costs for obtaining the 2017 Commitment Purchase Agreement were recorded as CHF 265,205 in transaction costs in the statement of profit or loss and comprehensive income / (loss). The commitment fee of CHF 290,400 (US$ 300,000 ) represents the fair value of the right to require LPC to purchase common shares within the 2017 Commitment Purchase Agreement. The proportion of the commitment fee CHF 35,073 related to cash received from common shares issued pursuant to the 2017 Commitment Purchase Agreement as a percentage of the total contract value of US$ 13.5 million is recognized in equity as if this proportion of the commitment fee was incorporated into the strike price of the option. The remaining portion of the commitment fee of CHF 255,327 was derecognized through transaction costs in the statement of profit and loss and comprehensive income / (loss) as the 2017 Commitment Purchase Agreement did not have any significant future value as of December 31, 2017 due the fact that the 2017 Commitment Purchase Agreement terminated upon consumption of Merger on March 13, 2018. Additionally, on October 16, 2017, the Company issued 1,744,186 of its common shares to LPC for aggregate proceeds of CHF 1,446,150 ( $1,500,000 ) pursuant to the Company's effective shelf registration statement on Form F-3. The related transaction cost of CHF 63,056 were recorded in equity. On February 21, 2017, the Company completed a public offering (the “February 2017 Offering”) of 10,000,000 common shares with a nominal value of CHF 0.40 each and 10,000,000 warrants, each warrant entitling its holder to purchase 0.70 of a common share. The gross proceeds to the Company from the February 2017 Offering were CHF 9,998,305 (US $10,000,000 ). The Company had transaction costs amounting to CHF 903,919 . The transactions costs were recorded as CHF 397,685 in equity for the issuance of the common shares and CHF 506,234 to finance expense in the statement of profit or loss and comprehensive loss for the issuance of the warrants. Issuance of common shares with restrictions For the business year 2015, 25,813 restricted common shares with a nominal value of CHF 0.40 were awarded and issued on January 7, 2016 under the Equity Incentive Plan for the purpose of share based bonus payments. The shares are fully vested on the grant date but remain subject to transfer restrictions for a period until January 7, 2019. The Company recorded a payroll charge of CHF 188,092 in 2015. Authorized share capital On January 17, 2019, the extraordinary general meeting of shareholders revised the provisions related to authorized and contingent capital of the Company and approved an increase and extension of the authorized share capital. As of December 31, 2018 , the Company’s authorized capital amounted to CHF 22,580.26 and allowed to Board of Directors, subject to the terms and conditions set forth in the Articles of Association, to issue up to 1,129,013 fully paid registered shares with a nominal value of CHF 0.02 each. Conditional share capital The share capital may be increased by the issuance of up to 1,630,613 fully paid registered Common Shares with a nominal value of CHF 0.02 per share and to the maximum amount of CHF 32,612.26 in execution of subscription rights, which may be granted to employees, members of the Board of Directors as well as key service providers (see Note 13 for further reference). The Company’s share capital may be further increased by the issuance of up to 11,771,002 fully paid registered Common Shares with a nominal value of CHF 0.02 per share and to the maximum amount of CHF 235,420.04 in execution of conversion rights in connection with warrants and convertible bonds of the Company. For the terms of the warrant issued to Hercules, refer to Note 24.

Share based compensation

Share based compensation	12 Months Ended
	Dec. 31, 2018
Share-based payment arrangements [Abstract]
Share based compensation	Share based compensation Description On November 21, 2008, the Company established share option programs (“Stock Option Plans A and B”) for employees, members of the Board of Directors as well as key service providers to purchase shares in the Company. Stock Option Plan A was amended and superseded by an updated version effective November 24, 2009, and replaced with amendments by Stock Option Plan C for any future option grants effective April 5, 2013. Grants under Stock Option Plan A and subsequently under Stock Option Plan C were offered in each year with vesting periods of three and four years ; grants under Stock Option Plan B were made in 2008, 2009 and 2014 only. Stock Option Plan B was abolished in 2015 and no grants under Stock Option Plan B were made in 2015. In 2014, the Group introduced a further equity incentive plan, the EIP. The Company granted 911,983 options in 2018 ( 2017 : 1,918,100 ) under the EIP. Holders of vested options are entitled to purchase common shares of the Company. For the stock option plans that were in place before the IPO, the exercise price corresponded to the value per share at the most recent financing round. Under the Equity Incentive Plan, the Board of Directors defined the exercise price as the average daily closing price of the Company’s shares during the 30 days preceding the date of grant. All options are to be settled by the physical delivery of shares. The key terms and conditions related to the grants under these programs are as at December 31, 2018 as follows: Plan Number of options outstanding Vesting conditions Contractual life of options Stock option Plan C 11,530 4 years' service from grant date 6 years Equity Incentive Plan Board 185,340 1 year service from grant date 8 years Equity Incentive Plan Employees / Board 405,280 2 years' service from grant date (50%) 8 years Equity Incentive Plan Employees / Board 390,627 3 years' service from grant date (50%) 8 years Measurement of fair values The fair value of the options was measured based on the Black-Scholes formula. Stock Option Plan Equity Incentive Equity Incentive Equity Incentive Equity Incentive Fair value at grant date USD 0.340 (1 year vesting) 1) USD 0.449 (2 year vesting) 1) USD 0.514 (3 year vesting) 1) USD 1.074 (1 year vesting) 2) USD 1.299 (2 year vesting) 2) USD 1.390 (3 year vesting) 2) USD 0.198 (1 year vesting) 1) USD 0.287 (2 year vesting) 1) USD 0.352 (3 year vesting) 1) USD 0.233 (1 year vesting) 2) USD 0.335 (2 year vesting) 2) USD 0.406 (3 year vesting) 2) Share price at grant date USD 0.64 USD 1.46 USD 0.76 USD 0.72 Exercise price USD 0.66 USD 1.58 USD 0.82 USD 0.82 Expected volatility 137.06% 93.38% 72.85% 93.01% Expected life 1,2 and 3 years 1,2 and 3 years 1,2 and 3 years 1,2 and 3 years Expected dividends — — — — Risk-free interest rate 3.06% 2.92% 2.38% 2.19% 1) October grants for the respective year 2) April grants for the respective year The Company uses its own historic volatility to calculate expected volatility. The expected life of all options is assumed to correspond to the vesting period. The total expense recognized for equity-settled share-based payment transactions were CHF 42,757 in 2018 ( 2017 : CHF 354,851 , 2016 : 290,783 ). Share based compensation loss related to employee stock options amounted to CHF 27,730 in 2018 ( 2017 : CHF 354,851 , 2016 : 290,783 ). Share based compensation expense of CHF 15,027 related to the purchase of intangibles was capitalized for the year ended December 31, 2018. The number and weighted average exercise prices (in CHF) of options under the share option programs for Stock Option Plan A, Stock Option Plan C and the EIP are as follows: 2018 2017 Number of options Weighted average exercise price Weighted average remaining term Number of options Weighted average exercise price Weighted average remaining term Outstanding at January 1 225,154 17.40 6.88 1,038,140 3.36 6.14 Expired during the year (5,000 ) — — (67,500 ) — — Forfeited during the year (139,360 ) — — (637,200 ) — — Exercised during the year — — — — — — Granted during the year 911,983 1.04 7.73 1,918,100 0.82 7.70 Outstanding at December 31 992,777 1.10 7.45 2,251,540 1.74 6.88 Exercisable at December 31 63,314 26.28 5.08 326,510 4.48 4.24 The range of exercise prices for outstanding options was CHF 0.66 to CHF 59.80 as of December 31, 2018 and CHF 0.80 to CHF 5.81 as of December 31, 2017 .

Trade and other payables

Trade and other payables	12 Months Ended
	Dec. 31, 2018
Subclassifications of assets, liabilities and equities [abstract]
Trade and other payables	Trade and other payables December 31, 2018 December 31, 2017 Trade accounts payable - third parties 1,810,445 1,032,557 Other 25,890 168,263 Total trade and other payables 1,836,335 1,200,820

Accrued expenses

Accrued expenses	12 Months Ended
	Dec. 31, 2018
Subclassifications of assets, liabilities and equities [abstract]
Accrued expenses	Accrued expenses December 31, 2018 December 31, 2017 Accrued research and development costs including milestone payments 700,866 4,060,048 Professional fees 315,657 227,363 Accrued vacation & overtime 54,557 69,455 Employee benefits incl. share based payments 146,949 217,649 Other 72,850 108,198 Total accrued expenses 1,290,879 4,682,713

Research and development expens

Research and development expense	12 Months Ended
	Dec. 31, 2018
Analysis of income and expense [abstract]
Research and development expense	Research and development expense December 31, 2018 December 31, 2017 December 31, 2016 Pre-clinical projects 873,453 642,821 546,429 Clinical projects 846,235 12,365,768 16,639,304 Drug manufacturing and substance 2,185,292 2,027,184 2,608,814 Employee benefits and expenses 1,652,791 2,773,516 2,854,624 Lease expenses 65,921 111,680 84,344 Patents and trademarks 634,986 603,892 941,836 Regulatory projects 398,426 632,387 1,043,287 Depreciation tangible assets 32,485 53,594 58,125 Total research and development expense 6,689,589 19,210,842 24,776,763

General and administrative expe

General and administrative expense	12 Months Ended
	Dec. 31, 2018
Analysis of income and expense [abstract]
General and administrative expense	General and administrative expense December 31, 2018 December 31, 2017 December 31, 2016 Employee benefits and expenses 1,084,112 2,097,853 2,174,543 Business development 43,816 161,985 45,649 Travel expenses 70,944 199,484 158,774 Administration expenses 2,797,526 2,522,217 2,969,796 Lease expenses 52,416 81,277 63,695 Depreciation tangible assets 186,520 69,190 39,475 Capital tax expenses 29,200 18,403 (5,420 ) Total general and administrative expenses 4,264,534 5,150,409 5,446,512

Employee benefits

Employee benefits	12 Months Ended
	Dec. 31, 2018
Employee Benefits [Abstract]
Employee benefits	Employee benefits December 31, 2018 December 31, 2017 December 31, 2016 Salaries 2,542,952 3,761,171 3,662,180 Pension costs 108,978 378,588 342,805 Other social benefits 188,138 277,468 301,537 Share based payments costs 27,730 354,851 290,783 Recruitment costs — 125,731 391,035 Other personnel expenditures (130,895 ) (26,439 ) 40,827 Total employee benefits 2,736,903 4,871,370 5,029,167 Benefit plans The Company participates in a retirement plan (the “Plan”) organized as an independent collective foundation, that covers all of its employees in Switzerland, including management. The collective foundation is governed by a foundation board. The board is made up of an equal number of employee and employer representatives of the affiliated companies. The Company has no direct influence on the investment strategy of the collective foundation. Moreover, certain elements of the employee benefits are defined in the same way for all affiliated companies. This is mainly related to the annuity factors at retirement and to interest allocated on retirement savings. The employer itself cannot determine the benefits or how they are financed directly. The foundation board of the collective foundation is responsible for the determination of the investment strategy, for making changes to the pension fund regulations and in particular, also for defining the financing of the pension benefits. The old age benefits are based on retirement savings for each employee, coupled with annual retirement credits and interest (there is no possibility to credit negative interest). At retirement age, the insured members can choose whether to take a pension for life, which includes a spouse’s pension, or a lump sum. In addition to retirement benefits, the plan benefits also include disability and death benefits. Insured members may also buy into the scheme to improve their pension provision up to the maximum amount permitted under the rules of the plan and may withdraw funds early for the purchase of a residential property for their own use subject to limitations under Swiss law. On leaving the Company, retirement savings are transferred to the pension institution of the new employer or to a vested benefits institution. This type of benefit may result in pension payments varying considerably between individual years. In defining the benefits, the minimum requirements of the Swiss Law on Occupational Retirement, Survivors and Disability Pension Plans (BVG) and its implementing provisions must be observed. The BVG defines the minimum pensionable salary and the minimum retirement credits. In Switzerland, the minimum interest rate applicable to these minimum retirement savings is set by the Swiss Federal Council at least once every two years. The rate was 1.25% in 2016 , 1.00% in 2017 and 1.00% in 2018. The assets are invested by the collective foundation in a diversified portfolio that respects the requirements of the Swiss BVG. Under the Plan, both the Company and the employee share the costs equally. The structure of the plan and the legal provisions of the BVG mean that the employer is exposed to actuarial risks. The main risks are investment risk, interest risk, disability risk and the risk of longevity. Through the affiliation to a collective foundation, the Company has minimized these risks, since they are shared between a much greater number of participants. The following tables present information about the net defined benefit liability and its components: Change in defined benefit obligation 2018 2017 Defined benefit obligation at January 1 7,999,617 7,122,841 Service costs 90,162 348,172 Plan participants' contribution 144,287 236,074 Interest cost 50,845 50,494 Actuarial losses (1,911,382 ) 60,781 Transfer-out amounts (3,367,834 ) (440,950 ) Transfer-in amounts of new employees 79,930 622,205 Defined benefit obligation at December 31 3,085,625 7,999,617 The defined benefit obligation includes only liabilities for active employees. The weighted average modified duration of the defined benefit obligation at December 31, 2018 is 21.8 years ( 2017 : 20.9 years ). Change in fair value of plan assets 2018 2017 Fair value of plan assets at January 1 6,036,647 5,030,407 Interest income 36,304 37,500 Return on plan assets excluding interest income (634,190 ) 332,759 Employer contributions 146,245 236,074 Plan participants' contributions 146,245 236,074 Transfer-out amounts (3,367,834 ) (440,950 ) Transfer-in amounts of new employees 79,930 622,205 Administration expense (6,009 ) (17,422 ) Fair value of plan assets at December 31 2,437,338 6,036,647 Net defined benefit liability recognized in the statement of financial position December 31, 2018 December 31, 2017 Present value of funded defined benefit obligation 3,085,625 7,999,617 Fair value of plan assets (2,437,338 ) (6,036,647 ) Net defined benefit liability 648,287 1,962,970 Defined Benefit Cost 2018 2017 2016 Service cost 90,162 348,172 319,173 Net interest expense 14,541 12,994 14,922 Administration expense 6,009 17,422 8,710 Total defined costs for the year recognized in profit or loss 110,712 378,588 342,805 Remeasurement of the Defined Benefit Liability 2018 2017 2016 Actuarial loss (gain) arising from changes in financial assumptions (119,117 ) (150,552 ) 412,396 Actuarial loss arising from experience adjustments (1,792,265 ) 211,331 264,417 Actuarial gain arising from demographic assumptions — — (258,876 ) Return on plan assets excluding interest income 634,190 (332,759 ) (23,835 ) Total defined benefit cost for the year recognized in the other comprehensive loss (1,277,192 ) (271,980 ) 394,102 Assumptions At December 31 2018 2017 2016 Discount rate 0.95 % 0.80 % 0.70 % Future salary increase 1.10 % 1.10 % 1.10 % Pension indexation 0.00 % 0.00 % 0.00 % Mortality and disability rates BVG2015G BVG2015G BVG 2015G Sensitivity analysis Reasonably possible changes at the reporting date to one of the relevant actuarial assumptions, holding other assumptions constant, would have affected the defined benefit obligation by the amounts shown below. December 31, 2018 2017 Change in assumption 0.25 % increase 0.25 % increase Discount rate (138,606 ) (354,477 ) Salary increase 13,121 49,707 Pension indexation 65,943 189,965 Change in assumption + 1 year + 1 year Life expectancy 60,369 182,977

Finance income and finance expe

Finance income and finance expense	12 Months Ended
	Dec. 31, 2018
Analysis of income and expense [abstract]
Finance income and finance expense	Finance income and finance expense 2018 2017 2016 Interest income — 53,570 67,565 Net foreign currency exchange gain 1,103,067 1,912,681 843,950 Revaluation gain from derivative financial instruments 1,350,071 3,372,186 291,048 Total finance income 2,453,138 5,338,437 1,202,563 Interest expense (incl. Bank charges) 1,070,177 1,640,394 828,547 Net foreign currency exchange loss 1,242,938 2,737,273 944,047 Total finance expense 2,313,115 4,377,667 1,772,594 Finance income/(expense), net 140,023 960,770 (570,031 ) In 2018 , net foreign currency exchange gains contain translation gains of CHF 264,029 ( 2017 : CHF 1,315,029 ; 2016 : CHF 396,665 ) which arose on the Company’s USD and EUR denominated cash and cash equivalents. In 2018 , interest expenses include interest paid to Hercules Capital, Inc. under the Loan and Security Agreement in an amount of CHF 435,993 ( 2017 : CHF 1,182,369 ; 2016 : CHF 546,170 ).

Taxation

Taxation	12 Months Ended
	Dec. 31, 2018
Income Taxes [Abstract]
Taxation	Taxation The Group’s income tax expense recognized in the consolidated statement of profit or loss and other comprehensive loss was as follows: 2018 2017 2016 Deferred income tax expense (294,056 ) (21,415 ) — Deferred income tax gain 131,879 39,188 131,055 (162,177 ) 17,773 131,055 The Group’s effective income tax expense differed from the expected theoretical amount computed by applying the Group’s applicable weighted average tax rate of 21.1% in 2018 ( 2017 : 21.7% , 2016 : 21.5% ) as summarized in the following table: Reconciliation 2018 2017 2016 Loss before income tax (11,334,224 ) (24,427,247 ) (30,793,306 ) Income tax at statutory tax rates applicable to results in the respective countries 2,397,177 5,311,030 6,629,237 Effect of unrecognized temporary differences 140,371 193,598 (27,072 ) Effect of unrecognized taxable losses (2,553,594 ) (5,429,935 ) (6,360,837 ) Effect of previously unrecognised deferred tax asset 114,116 39,189 131,055 Effect of expenses deductible for tax purposes — 9,696 2,505 Effect of expenses not considerable for tax purposes — — 23,716 Effect of impact from application of different tax rates (260,247 ) (105,805 ) (267,695 ) Effect of unrecognized taxable losses in equity — — 146 Income tax gain (162,177 ) 17,773 131,055 The tax effect of taxable temporary differences that give rise to deferred income tax liabilities or to deferred income tax assets as of December 31 is presented below: Deferred Tax Liabilities December 31, 2018 December 31, 2017 Intangible assets (627,540 ) (349,052 ) Hercules Loan Facility (889 ) (47,477 ) Derivative financial asset (17,763 ) — Total (646,192 ) (396,529 ) Deferred Tax Asset December 31, 2018 December 31, 2017 Net operating loss (NOL) 305,206 217,720 Total 305,206 217,720 Deferred Tax, net (340,986 ) (178,809 ) Deferred Tax 2018 Opening Balance Recognized in Profit or Loss Recognized in Equity Closing Balance Intangible assets (349,052 ) (276,293 ) (2,195 ) (627,540 ) Hercules Loan Facility (47,477 ) 46,588 — (889 ) Derivative financial asset — (17,763 ) — (17,763 ) Net operating loss (NOL) 217,720 85,291 2,195 305,206 Total (178,809 ) (162,177 ) — (340,986 ) Deferred Tax 2017 Opening Balance Recognized in Profit or Loss Recognized in Equity Closing Balance Intangible assets (327,637 ) (21,415 ) — (349,052 ) Hercules Loan Facility (76,390 ) 28,913 — (47,477 ) Net operating loss (NOL) 207,445 10,275 — 217,720 Total (196,582 ) 17,773 — (178,809 ) As of December 31, 2018 , the Group had total gross tax loss carry forwards amounting to CHF 151.4 million ( 2017 : CHF 142 million ), of which CHF 150.3 million related to Auris Medical AG, Auris Medical Holding AG and Otolanum AG in Switzerland and CHF 1.1 million to Auris Medical Inc. in the United States ( 2017 : CHF 140.9 million for Auris Medical AG and Otolanum AG and CHF 1.1 million for Auris Medical Inc.). The Group’s tax loss carry-forwards with their expiry dates are as follows: December 31, 2018 December 31, 2017 Within 1 year 8,173,993 1,754,398 Between 1 and 3 years 41,980,704 31,089,191 Between 3 and 7 years 100,136,349 108,055,089 More than 7 years 1,070,993 1,072,260 Total 151,362,039 141,970,938 The tax effect of the major unrecognized temporary differences and loss carry-forwards is presented in the table below: December 31, 2018 December 31, 2017 Deductible temporary differences Employee benefit plan 143,271 433,816 Stock option plans 148,407 400,764 Total potential tax assets 291,678 834,580 Taxable unrecognized temporary differences Property and equipment — — Total unrecognized potential tax liabilities — — Offsetting potential tax liabilities with potential tax assets — — Net potential tax assets from temporary differences not recognized 291,678 834,580 Potential tax assets from loss carry-forwards not recognized 31,387,022 29,959,963 Total potential tax assets from loss carry-forwards and temporary differences not recognized 31,678,700 30,794,543

Loss per share

Loss per share	12 Months Ended
	Dec. 31, 2018
Earnings per share [abstract]
Disclosure of earnings per share	Loss per share December 31, 2018 December 31, 2017 December 31, 2016 Loss attributable to owners of the Company (11,496,401 ) (24,409,474 ) (30,662,251 ) Weighted average number of shares outstanding * 15,900,865 4,374,187 3,432,928 Basic and diluted loss per share (0.72 ) (5.58 ) (8.93 ) * The basic and diluted loss per share for the year ended December 31, 2017 and the year ended December 31, 2016 is revised to reflect the reverse-split ratio of 10 to 1 following the Merger on March 13, 2018. For the years ended December 31, 2018 and 2017 basic and diluted loss per share is based on the weighted average number of shares issued and outstanding and excludes shares to be issued under the Stock Option Plans (Note 13) and the warrant issued to Hercules (Note 24) as they would be anti-dilutive. As of December 31, 2018 , the Company has 992,777 options outstanding under its stock option plans. The average number of options outstanding between January 1, 2018 and December 31, 2018 was 459,645 ( 1,676,526 for the period between January 1, 2017 and December 31, 2017 ). As of December 31, 2018 , the Company issued warrants to purchase up to 6,544,791 of its common shares outstanding.

Commitments and contingencies

Commitments and contingencies	12 Months Ended
	Dec. 31, 2018
Leases1 [Abstract]
Commitment and contingencies	Commitments and contingencies Operating lease commitments In August 2018, the Group assigned its lease agreement for its office space entered into on October 1, 2016 to a third party and entered into a new lease agreement for new office space with indefinite duration and a six-month cancellation period. The future minimum lease payments under non-cancellable operating leases that are not accounted for in the statement of financial position were as follows: December 31, 2018 December 31, 2017 Within one year 24,374 161,110 Between one and five years — 446,051 Total 24,374 607,161 Office lease expenses of CHF 118,337 , CHF 192,957 and CHF 148,039 were recorded in 2018 , 2017 and 2016 , respectively, in the consolidated statement of profit or loss and other comprehensive loss.

Loan and warrant

Loan and warrant	12 Months Ended
	Dec. 31, 2018
Financial Instruments [Abstract]
Loan and Warrant	Loan and Warrant On July 19, 2016, the Company entered into a Loan and Security Agreement (the “Hercules Loan and Security Agreement”) for a secured term loan facility of up to $ 20.0 million with Hercules Capital, Inc. as administrative agent (“Hercules”) and the lenders party thereto. An initial tranche of $ 12.5 million was drawn on July 19, 2016, concurrently with the execution of the Hercules Loan and Security Agreement. The loan matures on January 2, 2020 and bears interest at a minimum rate of 9.55% per annum, and is subject to the variability of the prime interest rate. The loan is secured by a pledge of the shares of Auris Medical AG owned by the Company, all intercompany receivables owed to the Company by its Swiss subsidiaries and a security assignment of the Company’s bank accounts. On April 5, 2018 the Company entered into an agreement with Hercules whereby the terms of the Hercules Loan and Security Agreement were amended to eliminate the $ 5 million liquidity covenant in exchange for a repayment of $ 5 million principal amount outstanding under the Hercules Loan and Security Agreement. The Company shall maintain a blocked cash account denominated in United States Dollars as a blocked account (the “Blocked Account”) as collateral for the remaining principal balance of the Secured Obligations and the End of Term Charge. The carrying value of the cash serving as collateral is USD 2,120,257 . The Blocked Account will be reduced on a dollar for dollar basis by the amount of such principal payments or end of term charge when such payments are received by Lender. Following the modification of the loan to repay $ 5 million , a loss of CHF 334,747 was recognized in connection with the modification of the loan and transaction costs. This loss is presented in the line interest expense in the condensed consolidated interim statement of profit or loss and other comprehensive income or loss. The loan was initially recognized at transaction value with deductions of the fair value of the warrant at transaction date and directly attributable transactions costs. Subsequent to initial recognition, the loan is measured at amortized cost using the effective interest method. Applying this method, the calculated value of the loan as of December 31, 2018 is CHF 1,435,400 . Of the CHF 1,435,400 amortization payments due within the next 12 months in an amount of CHF 1,435,400 are reclassified as current liabilities. In connection with the loan facility, the Company issued Hercules a warrant to purchase up to 241,117 of its common shares at an exercise price of $ 3.94 per share. As of July 19, 2016, the warrant was exercisable for 156,726 common shares. Upon Hercules making the second advance under the loan facility, the warrant shall become exercisable for the additional 84,391 common shares. The warrant expires on July 19, 2023. The fair value calculation of the warrant is based on the Black-Scholes option price model. Assumptions are made regarding inputs such as volatility and the risk free rate in order to determine the fair value of the warrant. As the warrant is part of the loan transaction, its fair value was deducted from the loan proceeds and accounted for separately as non-current financial liability. Following the initial recognition, the warrant is measured at fair value and the changes in fair value are shown as profit or loss. As of December 31, 2018 the fair value of the warrant amounts to CHF 3,804 . Therefore, the fair value decreased by the total amount of CHF 19,546 in the current year (2017: CHF 93,782 ). As of March 13, 2018, following the consummation of the Merger, the warrant was exercisable for 15,673 common shares at an exercise price of $39.40 per common share.

Related party transactions

Related party transactions	12 Months Ended
	Dec. 31, 2018
Related Party [Abstract]
Related party transactions	Related party transactions For purposes of these consolidated financial statements, parties are considered to be related if one party has the ability to control the other party or exercise significant influence over the other party in making financial or operational decisions. Also, parties under common control of the Group are considered to be related. Key management personnel are also related parties. In considering each possible related party relationship, attention is directed to the substance of the relationship, and not merely the legal form. Compensation of the members of the Board of Directors and Management In 2018 , the total compensation paid to management amounted to CHF 1,403,250 ( 2017 : CHF 1,973,167 ; 2016 : CHF 1,871,406 ). The fees paid to members of the Board of Directors in 2018 for their activities as board members totaled CHF 287,384 ( 2017 : CHF 337,619 ; 2016 : CHF 364,276 ). Up to the Company’s IPO, non-executive directors received part or all of their remuneration in stock options; travel and out of pocket expenses were reimbursed in cash by the Group. Executive directors and directors delegated and remunerated by a shareholder for its representation on the Board were not entitled to any specific remuneration for their Board membership and work. Following the IPO, the Board’s remuneration policy was modified in that all non-executive directors received remuneration for their work as members of the Board as well as of the newly constituted Compensation Committee and Audit Committee. Executive Management Board of Directors Total 2018 2017 2016 2018 2017 2016 2018 2017 2016 Short term benefits 1,002,707 1,576,864 1,554,850 200,421 280,762 325,493 1,203,128 1,857,626 1,880,343 Post-employee benefits years 55,278 94,839 88,838 — — — 55,278 94,839 88,838 Share-based payment charge 204,224 190,659 217,981 60,657 72,647 103,380 264,881 263,306 321,361 Total 1,262,209 1,862,362 1,861,669 261,078 353,409 428,873 1,523,287 2,215,771 2,290,542 In 2018 , CHF 264,881 ( 2017 : CHF 263,306 ; 2016 : CHF 321,361 ) was expensed for grants of stock options to members of the Board of Directors and management. The 2018 share based payment charge shown above excludes adjustments for instruments forfeited in 2018 due to termination of service. Contributions to pension schemes amounted to CHF 55,278 , CHF 94,839 and CHF 88,838 during the years 2018 , 2017 and 2016 , respectively. No termination benefits or other long term benefits were paid. Members of the Board of Directors and management held 703,235 , 1,782,605 and 656,355 stock options as of December 31, 2018 , 2017 , and 2016 , respectively. Related Party Transaction On February 9, 2018, Thomas Meyer, our Chief Executive Officer, entered into a shares transfer agreement with the Company to facilitate the rounding up of fractional shares resulting from the exchange ratio used in the Merger. Pursuant to the terms of the share transfer agreement, Mr. Meyer has committed to transfer, at no consideration, a common share to any shareholder entitled to a fraction of a common share as part of the Merger. Pursuant to the share transfer agreement, the Company nor the Mr. Meyer will receive any compensation for this arrangement. Any expenses incurred by Mr. Meyer in connection with the transfers under such agreement were borne by the Company. Controlled Equity Offering SM Thomas Meyer, the Company's Chief Executive Officer, or the Share Lender, has entered into a share lending agreement with Cantor to facilitate the timely settlement of common shares sold under the Controlled Equity Offering Sales Agreement with Cantor. Pursuant to the terms of the share lending agreement, the Share Lender will lend common shares to Cantor so that those common shares may be delivered by Cantor to purchasers of common shares sold in the offering. Cantor will return common shares to the Share Lender upon the issuance of new common shares by the Company to Cantor. Neither the Company nor the Share Lender received any compensation for this arrangement. In the year ended December 31, 2017, the Company did not offer or sell any common shares under the Controlled Equity Offering Sales Agreement. The Controlled Equity Offering program terminated upon consummation of the Merger on March 13, 2018.

Warrants from Public Offering

Warrants from Public Offering	12 Months Ended
	Dec. 31, 2018
Share capital, reserves and other equity interest [Abstract]
Warrants from Public Offering	Warrants from Public Offering On February 21, 2017, the Company completed a public offering (the “February 2017 Offering”) of 10,000,000 common shares with a nominal value of CHF 0.40 each and 10,000,000 warrants, each warrant entitling its holder to purchase 0.70 of a common share. The net proceeds to the Company from the February 2017 Offering were approximately CHF 9.1 million (US$ 9.1 million ), after deducting underwriting discounts and other estimated offering expenses payable by us. The Company had transaction costs amounting to CHF 903,919 . The transactions costs were recorded as CHF 397,685 in equity for the issuance of the common shares and CHF 506,234 to finance expense in the statement of profit or loss and comprehensive loss for the issuance of the warrants. The underwriter was granted a 30 -day option to purchase up to 1,500,000 additional common shares and/or 1,500,000 additional warrants. On February 15, 2017, the underwriter partially exercised its 30 -day option to purchase additional common shares and/or warrants in the amount of 1,350,000 warrants. Consequently, the Company issued warrants to purchase up to 7,945,000 of its common shares at an exercise price of US$ 1.2 per share. The warrants are exercisable during a five-year period beginning on date of issuance. The fair value calculation of the warrants is based on the Black-Scholes option price model. Assumptions are made regarding inputs such as volatility and the risk free rate in order to determine the fair value of the warrant. If a warrant is exercised, the Company will receive variable proceeds because the Company’s functional currency is CHF and the exercise price is in USD, which results in the warrants being considered liability instruments. Therefore, the warrants were assigned fair values using the Black-Scholes model. The residual value was assigned to the common share sold along with each warrant in accordance with IAS 32 Financial instruments. The gross proceeds from the February 2017 offering were CHF 9,998,305 of which CHF 5,091,817 (fair value as of February 21, 2017) was assigned to the warrants and CHF 4,906,488 was assigned to equity. As of December 31, 2018, the fair value of the warrants amounted to CHF 166,301 (2017: 1,813,413 ). The fair value decreased by CHF 1,647,112 resulting in a revaluation gain of the same amount for the year ended December 31, 2018. As of March 13, 2018, following the consummation of the Merger, the outstanding warrants issued in the February 2017 Offering are excisable for up to 794,500 common shares at an exercise price of $12.00 per common share. On January 30, 2018, the Company issued 7,499,999 warrants in connection with a direct offering of 12,499,999 common shares, each warrant entitling its holder to purchase one common share at an exercise price of $0.50 per common share. As of March 13, 2018, following the consummation of the Merger, the warrants became exercisable for an aggregate of 750,002 of our common shares (assuming the Company decides to round up fractional common shares to the next whole common share), at an exercise price of $5.00 per common share. As of December 31, 2018 the fair value of the warrants amounted CHF 289,651 . Since its initial recognition on January 30, 2018, the fair value of the warrants has decreased by CHF 2,194,096 , resulting in a gain in the corresponding amount (fair value as of January 30, 2018: CHF 2,483,747 ). On July 17, 2018, the Company issued 6,282,051 Series A warrants and 4,487,178 Series B warrants in connection with the July 2018 Registered Offering of 17,948,717 common shares, each warrant entitling its holder to purchase one common share at an exercise price of CHF 0.39 per common share. Revaluation gain/(loss) show the changes in fair value of the outstanding Series B warrant issued in connection with this offering. As of December 31, 2018, 2,904,518 Series A warrants were exercised for an aggregate amount of CHF 1,132,762 and 2,864,422 Series B warrants were exercised for an aggregate amount of CHF 1,117,125 . As of December 31, 2018, 2,864,422 Series B exercised warrants were subject to revaluation at the time that they were exercised and the fair value amounted to CHF 3,005,348 . Since its initial recognition on July 17, 2018 the fair value of the warrants has increased by CHF 2,433,098 , resulting in a loss in the corresponding amount (fair value as of July 17, 2018: CHF 572,249 ). As of December 31, 2018, the number of Series B warrants outstanding subject to revaluation were 690,702 and the fair value of the amounted to CHF 215,572 . Since its initial recognition on July 17, 2018, the fair value of the warrants has increased by CHF 77,585 , resulting in a loss in the corresponding amount (fair value as of July 17, 2018: CHF 137,987 ).

Events after the balance sheet

Events after the balance sheet date	12 Months Ended
	Dec. 31, 2018
Events After Reporting Period [Abstract]
Events after balance sheet date	Events after the balance sheet date Equity Offering As of March 14, 2019, the Company had issued an aggregate of 1,979,074 common shares under the "At-the-market" agreement with AGP for a total amount of $978,415 . Redomestication On January 24, 2019, the Company's board of directors determined that it would be in the Company's best interest to change its legal seat and jurisdiction of incorporation, respectively, from Switzerland to Bermuda pursuant to the Redomestication. the Company's shareholders approved the Redomestication and adopted the Memorandum of Continuance and the Bye-laws at an extraordinary general meeting of shareholders held on March 8, 2019. The Company expects to effect the Redomestication prior to the end of March 2019.

Significant accounting polici_2

Significant accounting policies (Policies)	12 Months Ended
	Dec. 31, 2018
Corporate Information and Statement of IFRS Compliance [Abstract]
Basis of consolidation	Basis of consolidation Subsidiaries Subsidiaries are entities controlled by the Group. The Group controls an entity when it is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. The financial statements of subsidiaries are included in the consolidated financial statements from the date on which control commences until the date on which control ceases. Transactions eliminated on consolidation All inter-company balances, transactions and unrealized gains on transactions have been eliminated in consolidation. Unrealized losses are also eliminated unless the transaction provides evidence of an impairment of the asset transferred.
Segment reporting	Segment reporting A segment is a distinguishable component of the Group that engages in business activities from which it may earn revenues and incur expenses, including revenues and expenses that relate to transactions with any of the Group’s other components. The Chief Executive Officer is determined to be the Group’s Chief Operating Decision Maker (“CODM”). The CODM assesses the performance and allocates the resources of the Group as a whole, as all of the Group’s activities are focusing on the development of pharmaceutical products for the treatment of inner ear and vestibular disorders. Financial information is only available for the Group as a whole. Therefore, management considers there is only one operating segment under the requirements of IFRS 8, Operating Segments.
Foreign currency	Foreign currency Foreign currency transactions Items included in the financial statements of Group entities are measured using the currency of the primary economic environment in which the entity operates. Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized in profit or loss. Non-monetary items that are measured based on historical cost in a foreign currency are not re-translated. Foreign operations Assets and liabilities of Group entities whose functional currency is other than CHF are included in the consolidation by translating the assets and liabilities into the reporting currency at the exchange rates applicable at the end of the reporting period. Income and expenses are translated at average exchange rates (unless this average is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, in which case income and expenses are translated at the dates of the transaction). These foreign currency translation differences are recognized in Other Comprehensive Loss and presented in the foreign currency translation reserve in equity. When a foreign operation is disposed of such that control is lost, the cumulative amount in the translation reserve related to that foreign operation is reclassified to profit or loss as part of the gain or loss on disposal.
Property and equipment	Property and equipment Property and equipment is measured at historical costs less accumulated depreciation and any accumulated impairment losses. Historical costs include expenditures that are directly attributable to the acquisition of the items. When parts of an item of tangible assets have different useful lives, they are accounted for as separate tangible asset items (major components). Depreciation is calculated on a straight-line basis over the expected useful life of the individual asset or the shorter remaining lease term for leasehold improvements. The applicable estimated useful lives are as follows: Production equipment 5 years Office furniture and electronic data processing equipment (“EDP”) 3 years Leasehold improvements 5 years Subsequent costs are included in the asset’s carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Group and the cost of the item can be measured reliably. The carrying amount of the replaced part is derecognized. All other repairs and maintenance are charged to profit or loss during the financial period in which they are incurred. Depreciation methods, useful lives and residual values are reviewed at each reporting date and adjusted if appropriate. When an asset is reviewed for impairment, the asset’s carrying amount may be written down immediately to its recoverable amount, provided the asset’s carrying amount is greater than its estimated recoverable amount. Management assesses the recoverable amount by assessing the higher of its fair value less costs to sell or its value in use. Cost and accumulated depreciation related to assets retired or otherwise disposed are removed from the accounts at the time of retirement or disposal and any resulting gain or loss is included in profit or loss in the period of disposition.
Intangible assets	Intangible assets Research and development Expenditures on the Group’s research programs are not capitalized, they are expensed when incurred. Expenditures on the Group’s development programs are generally not capitalized except if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Group intends to and has sufficient resources to complete development and to use or sell the asset. For the development projects of the Group, these criteria are generally only met when regulatory approval for commercialization is obtained. This has been the general assessment for AM-101, AM-111 and AM-201. For the AM-125 program for the treatment of Vertigo it is the Group assessment that the criteria mention above is met and therefore direct development expenditures have been capitalized for AM-125 in 2018. Intellectual property-related costs for patents are part of the expenditure for research and development projects. Therefore, registration costs for patents are expensed when incurred as long as the research and development project concerned does not meet the criteria for capitalization. Licenses, intellectual property and data rights Intellectual property rights that are acquired by the Group are capitalized as intangible assets if they are controlled by the Group, are separately identifiable and are expected to generate future economic benefits, even if uncertainty exists as to whether the research and development will ultimately result in a marketable product. Consequently, upfront and milestone payments to third parties for the exclusive use of pharmaceutical compounds in specified areas of treatment are recognized as intangible assets. Measurement Intangible assets acquired that have finite useful lives are measured at cost less accumulated amortization and any accumulated impairment losses. Subsequent expenditure Subsequent expenditure is capitalized only when it increases the future economic benefits embodied in the specific asset to which it relates. All other expenditure, including expenditure on internally generated goodwill and brands, is recognized in profit or loss as incurred. Amortization All licenses of the Group have finite lives. Amortization will commence once the Group’s intangible assets are available for use which will be the case after regulatory approvals are obtained and the related products are available for use. Amortization of licenses is calculated on a straight line basis over the period of the expected benefit or until the license expires, whichever is shorter. The estimated useful life is 10 years or the remaining term of patent protection. The Group assesses at each statement of financial position date whether intangible assets which are not yet ready for use are impaired.
Impairment of non-financial assets	Impairment of non-financial assets Property and equipment and intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. For the purpose of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash flows (cash-generating units). An impairment loss is recognized as the amount by which the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s fair value less costs to sell or value in use. Impairment losses are recognized in profit or loss. Assets that were previously impaired are reviewed for possible reversal of the impairment at each reporting date. Any increase in the carrying amount of an asset will be based on the depreciated historical costs had the initial impairment not been recognized.
Financial instruments	Financial instruments The Group classifies its financial assets in the following categories: loans and receivables based on the expected loss model. The classification depends on the nature and purpose of the financial assets and is determined at the time of initial recognition. The date of initial application (i.e. the date on which the Company has assessed its existing financial assets and financial liabilities in terms of IFRS 9 requirements) is January 1, 2018. Accordingly, the Company has applied the requirements of IFRS 9 to instruments that continue to be recognized at January 1, 2018 whereas for the year ended December 31, 2017 IAS 39 was applied. Recognition and derecognition of non-derivative financial assets and liabilities The Group initially recognizes loans and receivables and debt securities issued on the date when they are originated. All other financial assets and financial liabilities are initially recognized on the trade date. The Group derecognizes a financial asset when the contractual rights to the cash flows from the asset expire, or it transfers the rights to receive the contractual cash flows in a transaction in which substantially all of the risks and rewards of ownership of the financial asset are transferred, or it neither transfers nor retains substantially all of the risks and rewards of ownership and does not retain control over the transferred asset. Any interest in such derecognized financial assets that is created or retained by the Group is recognized as a separate asset or liability. The Group derecognizes a financial liability when its contractual obligations are discharged, cancelled, or expired. Financial assets and financial liabilities are offset and the net amount presented in the statement of financial position when, and only when, the Group has a legal right to offset the amounts and intends either to settle them on a net basis or to realize the asset and settle the liability simultaneously. Non-derivative financial assets and liabilities—measurement Loans and receivable These are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. Loans and receivables are initially recognized at fair value plus any directly attributable transaction costs. Subsequent to initial recognition, they are measured at amortized cost using the effective interest method, less expected losses. Cash and cash equivalents The Group considers all short-term, highly liquid investments that are readily convertible into known amounts of cash and which are subject to an insignificant risk of changes in value with original maturities of three months or less at the date of the purchase to be cash equivalents. Non-derivative financial liabilities—measurement Non-derivative financial liabilities are initially recognized at fair value less any directly attributable transaction costs. Subsequent to initial recognition, these liabilities are measured at amortized cost using the effective interest method. Share capital All shares of the Company are registered shares and classified as part of shareholders’ equity. Incremental costs directly attributable to the issue of the Company’s shares, net of any tax effects, are recognized as a deduction from equity. The warrants are classified as a financial liability at fair value through profit or loss and the cost allocated to the liability component will be immediately expensed to the income statement. The Company has not paid any dividends since its inception and does not anticipate paying dividends in the foreseeable future. Repurchase and reissue of ordinary shares (treasury shares) When shares recognized as equity are repurchased, the amount of the consideration paid, which includes directly attributable costs, net of any tax effects, is recognized as a deduction from equity. Repurchased shares are classified as treasury shares and are presented in the treasury share reserve. When treasury shares are sold or reissued subsequently, the amount received is recognized as an increase in equity and the resulting surplus or deficit (calculated as the difference between initial cost and fair value) on the transaction is presented within share premium.
Impairment of non-derivative financial assets	Impairment of non-derivative financial assets Financial assets are assessed at each reporting date to determine whether there is objective evidence of impairment. Objective evidence that financial assets are impaired includes: • default or delinquency by a debtor; • indications that a debtor or issuer will enter bankruptcy; • adverse changes in the payment status of borrowers or issuers; • the disappearance of an active market for a security; or • observable data indicating that there is measurable decrease in expected cash flows from a group of financial assets. Financial assets measured at amortized cost The Group considers evidence of impairment for these assets at an individual asset level. An impairment loss is calculated as the difference between an asset’s carrying amount and the present value of the estimated future cash flows discounted at the asset’s original effective interest rate. Losses are recognized in profit or loss and reflected in an allowance account. When the Group considers that there are no realistic prospects of recovery of the asset, the relevant amounts are written off. If the amount of impairment loss subsequently decreases and the decrease can be related objectively to an event occurring after the impairment was recognized, then the previously recognized impairment loss is reversed through profit or loss.
Derivative Financial Instruments	Derivative Financial Instruments Derivative financial instrument (asset) is accounted as the cost to obtain the rights from a third party to issue shares under the purchase agreement and changes in fair value are shown as profit or loss. The fair value calculation of the derivative financial instrument (asset) is adjusted on the utilization of the asset based on total dollar amount of the purchase agreement. Derivative financial instruments (liabilities) are accounted at fair value and changes in fair value are shown as profit or loss. The fair value calculation of the derivative financial instruments is based on the Black-Scholes option pricing model. Assumptions are made for volatility and the risk free rate in order to estimate the fair value of the instrument. Transaction cost related to derivative financial instruments are recorded through profit and loss.
Income tax	Income taxes As disclosed in Note 20 the Group has significant tax losses in Switzerland. These tax losses represent potential value to the Group to the extent that the Group is able to create taxable profits in Switzerland prior to expiry of such losses. Tax losses may be used within 7 years from the year the losses arose. The Group also has tax losses in the United States which may be used within 20 years of the end of the year in which losses arose, or for a shorter time period in accordance with prevailing state law. Other than a tax asset in the amount of CHF 305,206 , the Group has not recorded any deferred tax assets in relation to these tax losses. The key factors which have influenced management in arriving at this evaluation are the fact that the business is still in a development phase and the Group has not yet a history of making profits. Should management’s assessment of the likelihood of future taxable profits change, a deferred tax asset will be recorded. Income tax gain reflects the reassessment of deferred tax assets and liabilities booked in the 2018 fiscal year. Income tax Income tax expense comprises current and deferred tax. It is recognized in profit or loss except to the extent that it relates to a business combination, or items recognized directly in equity or in Other Comprehensive Income. Current tax Current tax comprises the expected tax payable or receivable on the taxable income or loss for the year and any adjustment to tax payable or receivable in respect of previous years. It is measured using tax rates enacted or substantively enacted at the reporting date. Deferred tax Deferred income tax is recognized, using the balance sheet liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the consolidated financial statements. Deferred tax is not recognized for: • temporary differences on the initial recognition of assets or liabilities in a transaction that is not a business combination and that affects neither accounting nor taxable profit or loss; • temporary differences related to investments in subsidiaries to the extent that the Group is able to control the timing of the reversal of the temporary differences and it is probable that they will not reverse in the foreseeable future; and • taxable temporary differences arising on the initial recognition of goodwill. Deferred income tax is determined using tax rates and laws that have been enacted or substantively enacted by the reporting date and are expected to apply when the related deferred income tax asset is realized or the deferred income tax liability is settled. Deferred income tax assets are recognized to the extent that it is probable that future taxable profit will be available against which the temporary differences can be utilized. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realized. Deferred tax assets and liabilities are offset when there is a legally enforceable right to set off tax assets against tax liabilities and when they relate to income taxes levied by the same taxation authority and the Group intends to settle its tax assets and liabilities on a net basis.
Employee benefits	Employee benefits The Group maintains a pension plan for all employees in Switzerland through payments to a legally independent collective foundation. This pension plan qualifies under IFRS as defined benefit pension plan. The Group’s net obligation in respect of defined benefit plans is calculated by estimating the amount of future benefit that employees have earned in return for their service in the current and prior periods, discounting that amount and deducting the fair value of any plan assets. The Company makes relevant actuarial assumptions with regard to the discount rate, future salary increases and life expectancy. Employee benefits The Group maintains a pension plan for all employees in Switzerland through payments to a legally independent collective foundation. This pension plan qualifies under IFRS as defined benefit pension plan. There are no pension plans for the subsidiaries in Ireland and the United States. The Group’s net obligation in respect of defined benefit plans is calculated by estimating the amount of future benefit that employees have earned in return for their service in the current and prior periods, discounting that amount and deducting the fair value of any plan assets. The recognized asset is limited to the present value of economic benefits available in the form of any future refunds from the plan or reductions in future contributions to the plan. In order to calculate the present value of economic benefits, consideration is given to any minimum funding requirements. Remeasurements of the net defined benefit liability, which comprise actuarial gains and losses, the return on plan assets (excluding interest) and the effect of the asset ceiling (if any, excluding interest), are recognized immediately in Other Comprehensive Income. Past service costs, including curtailment gains or losses, are recognized immediately in general and administrative expenses within the operating results. Settlement gains or losses are recognized in general and administrative expenses within the operating results. The Group determines the net interest expense (income) on the net defined benefit liability (asset) for the period by applying the discount rate used to measure the defined benefit obligation at the beginning of the annual period or in case of any significant events between measurement dates to the then-net defined benefit liability (asset), taking into account any changes in the net defined benefit liability (asset) during the period as a result of contributions and benefit payments. Net interest expense and other expenses related to defined benefit plans are recognized in profit or loss.
Considering reorganization / Merger	Considering reorganization / Merger The Merger is not a business combination and is accounted for as a reorganization. Therefore, the consolidated financial statements of the Company are a continuation of the financial information of Auris Old Co except that the consolidated financial statements reflect a classification between share capital and share premium in order to reflect the share capital of Auris NewCo. For the periods prior to the Merger, in calculating loss per share, the weighted average number of shares outstanding is calculated based on the number of weighted average shares issued by Auris Old Co, adjusted for the reverse stock split ratio of 10-for-1
Share-based compensation	Share-based compensation The Company maintains various share-based payment plans in the form of stock option plans for its employees, members of the Board of Directors as well as key service providers. Stock options are granted at the Board’s discretion without any contractual or recurring obligations. The share-based compensation plans qualify as equity settled plans. The grant-date fair value of share-based payment awards granted to employees is recognized as an expense, with a corresponding increase in equity, over the period that the employees become unconditionally entitled to the awards. The vesting of share options is conditional on the employee completing a period of service of three and four years respectively, from the grant date, in accordance with Stock Option Plans A and C. Under the Auris Medical Holding AG Long Term Equity Incentive Plan (the “Equity Incentive Plan” or “EIP”), 50% of granted share options granted to employees vest after a period of service of two years from the grant date and the remaining 50% vest after a period of service of three years from the grant date. Share options granted to members of the Board of Directors in 2018, 2017 and in 2016 vest after a period of one year after the grant date. Stock Option Plan B was created to provide shares for share based compensation plans; it was used in the years 2008, 2009 and 2014 and was abolished in 2015. The amount recognized as an expense is adjusted to reflect the number of awards for which the related service and non-market performance conditions are expected to be met, such that the amount ultimately recognized as an expense is based on the number of awards that meet the related service and non-market performance conditions at the vesting date. Share-based payments that are not subject to any further conditions are expensed immediately at grant date. In the year the options are exercised the proceeds received net of any directly attributable transaction costs are credited to share capital (nominal value) and share premium. Valuation of share options Following the completion of the Company's initial public offering, option pricing and values are determined based on the Black Scholes option pricing model and assumptions are made for inputs such as volatility of the Company's stock and the risk free rate.
Provisions	Provisions Provisions are recognized when the Group has a present obligation (legal or constructive) as a result of a past event, where it is more likely than not that an outflow of resources will be required to settle the obligation, and where a reliable estimate can be made of the amount of the obligation. Provisions are not recognized for future operating losses. Provisions are measured at the present value of the expenditures expected to be required to settle the obligation using a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability.
Leases	Leases Leases in which a significant portion of the risks and rewards of ownership are retained by the lessor are classified as operating leases. Payments made under operating leases (net of any incentives received from the lessor) are charged to profit or loss on a straight-line basis over the period of the lease.
Earnings/(loss) per share	Earnings/(loss) per share Basic earnings/(loss) per share are calculated by dividing the net profit/(loss) attributable to owners of the Company by the weighted average number of shares outstanding during the period. Diluted earnings/(loss) per share are calculated by dividing the net profit/(loss) attributable to the owners of the Company by the weighted average number of shares outstanding during the period adjusted for the conversion of all dilutive potential ordinary shares.
Statement of compliance	Statement of compliance These consolidated financial statements have been prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board (“IFRS”).
Basis of measurement	Basis of measurement The consolidated financial statements are prepared on the historical cost basis, except for the revaluation to fair value of certain financial liabilities. Historical cost is generally based on the fair value of the consideration given in exchange for goods and services. The principal accounting policies adopted are set out below. In addition, for financial reporting purposes, fair value measurements are categorized into Level 1, 2 or 3 based on the degree to which the inputs to the fair value measurements are observable and the significance of the inputs to the fair value measurement in its entirety, which are described as follows: • Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date • Level 2 inputs are inputs, other than quoted prices included within Level 1, that are observable for the asset or liability, either directly or indirectly; and • Level 3 inputs are unobservable inputs for the asset or liability.
Use of estimates and judgments	Use of estimates and judgments The preparation of financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions of accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. Information about judgments made in applying accounting policies that have the most significant effects on the amounts recognized in the consolidated financial statements are described below.
Development expenditures	Development expenditures The project stage forms the basis for the decision as to whether costs incurred for the Group’s development projects can be capitalized. For AM-101, AM-111 and AM-201 clinical development expenditures are not capitalized until the Group obtains regulatory approval (i.e. approval to commercially use the product), as this is considered to be essentially the first point in time where it becomes probable that future revenues can be generated. For the Group's intranasal betahistine program for the treatment of vertigo (AM-125), however, the development program of intranasal betahistine is primarily focused on the delivery route and formulation and not the drug itself (already an approved generic) and to demonstrate higher bioavailability through intranasal delivery. Given the nature of the development approach and the fact that there is an existing market in which oral betahistine for the treatment of vertigo has been approved, direct development expenditures have been capitalized. In addition, the Group has capitalized certain milestone payments with regard to license payments. As of each reporting date, the Group estimates the level of service performed by the vendors and the associated costs incurred for the services performed. As part of the process of preparing the Group’s financial statements, the Group is required to estimate its accrued expenses. This process involves reviewing contracts, identifying services that have been performed on the Group’s behalf and estimating the level of service performed and the associated cost incurred for the service when it has not yet been invoiced or otherwise notified of the actual cost.

Significant accounting polici_3

Significant accounting policies (Tables)	12 Months Ended
	Dec. 31, 2018
Corporate Information and Statement of IFRS Compliance [Abstract]
Disclosure of closing and average exchange rates for the most significant foreign currencies	Closing rates for the most significant foreign currencies relative to CHF: Currency Geographical area Reporting entities December 31, 2018 December 31, 2017 December 31, 2016 CHF Swiss Franc Switzerland 3 1.0000 1.0000 1.0000 USD Dollar United States 1 0.9827 0.9725 1.0196 EUR Europe Europe 1 1.1283 1.1713 1.0723 Average exchange rates for the year for the most significant foreign currencies relative to CHF: Currency Geographical area Reporting entities 2018 2017 2016 CHF Swiss Franc Switzerland 3 1.0000 1.0000 1.0000 USD Dollar United States 1 0.9768 0.9849 0.9855 EUR Europe Europe 1 1.1573 1.1116 1.0901
Disclosure of applicable estimated useful lives	The applicable estimated useful lives are as follows: Production equipment 5 years Office furniture and electronic data processing equipment (“EDP”) 3 years Leasehold improvements 5 years Production equipment Office furniture and EDP Leasehold improvements Total At cost As of January 1, 2017 283,499 233,706 236,462 753,667 Additions 6,389 — — 6,389 As of December 31, 2017 289,888 233,706 236,462 760,056 Additions — — — — Disposals — — (236,462 ) (236,462 ) As of December 31, 2018 289,888 233,706 — 523,594 Accumulated depreciation As of January 1, 2017 (184,329 ) (183,710 ) (16,334 ) (384,373 ) Charge for the year (53,594 ) (21,918 ) (47,272 ) (122,784 ) As of December 31, 2017 (237,923 ) (205,628 ) (63,606 ) (507,157 ) Charge for the year (32,485 ) (13,663 ) (26,565 ) (72,713 ) Disposals — — 90,171 90,171 As of December 31, 2018 (270,408 ) (219,291 ) — (489,699 ) Net book value As of December 31, 2017 51,965 28,078 172,856 252,899 As of December 31, 2018 19,480 14,415 — 33,895

New standards, amendments and_2

New standards, amendments and interpretations adopted by the Group (Tables)	12 Months Ended
	Dec. 31, 2018
Accounting Policies, Accounting Estimates And Errors [Abstract]
Disclosure of initial application of standards or interpretations	A number of new standards, amendments to standards and interpretations are effective for annual periods beginning after January 1, 2019 , and have not been applied in preparing these consolidated financial statements. Standard/Interpretation Impact Effective date Planned application by the Group New standards, interpretations or amendments IFRS 16 Leases 1) January 1, 2019 FY 2019 IFRIC 23 Uncertainty over Income Tax Positions 2) January 1, 2019 FY 2019 IFRS 9 Amendments to IFRS 9, Prepayment Features with negative Compensation 2) January 1, 2019 FY 2019 IAS 28 Amendments to IAS 28, Long-term Interests in Associates and Joint Ventures 2) January 1, 2019 FY 2019 IAS 19 Amendments to IAS 19, Plan Amendment, Curtailment or Settlement 2) January 1, 2019 FY 2019 Various Annual Improvements to IFRS Standards 2015-2017 Cycle. 2) January 1, 2019 FY 2019 Various Amendments to References to Conceptual Framework in IFRS Standards. 2) January 1, 2020 FY 2020 IFRS 17 Insurance contracts 2) January 1, 2021 FY 2021

Financial instruments and ris_2

Financial instruments and risk management (Tables)	12 Months Ended
	Dec. 31, 2018
Financial Instruments [Abstract]
Disclosure of the carrying amounts of financial assets	The following table shows the carrying amounts of financial assets and financial liabilities: Financial assets December 31, 2018 December 31, 2017 Cash and cash equivalents 5,393,207 14,973,369 Loans and receivables Other receivables 80,040 79,840 Total financial assets 5,473,247 15,053,209 Financial liabilities At amortized cost Trade and other payables 1,836,335 1,200,820 Accrued expenses 1,290,879 4,395,609 Loan 1,435,400 10,126,406 At fair value through profit and loss Derivative financial instruments 675,328 1,836,763 Total financial liabilities 5,237,942 17,559,598
Disclosure of the carrying amounts of financial liabilities	The following table shows the carrying amounts of financial assets and financial liabilities: Financial assets December 31, 2018 December 31, 2017 Cash and cash equivalents 5,393,207 14,973,369 Loans and receivables Other receivables 80,040 79,840 Total financial assets 5,473,247 15,053,209 Financial liabilities At amortized cost Trade and other payables 1,836,335 1,200,820 Accrued expenses 1,290,879 4,395,609 Loan 1,435,400 10,126,406 At fair value through profit and loss Derivative financial instruments 675,328 1,836,763 Total financial liabilities 5,237,942 17,559,598
Disclosure of remaining contractual maturities of non-derivative financial liabilities	The table below analysis the remaining contractual maturities of financial liabilities, including estimated interest payments as of December 31, 2018 and 2017 . The amounts disclosed in the table are the undiscounted cash flows: Carrying amount Less than 3 months Between 3 months and 2 years 2 years and later Total December 31, 2018 Trade and other payables 1,836,335 1,836,335 — — 1,836,335 Accrued expenses 1,290,879 1,290,879 — — 1,290,879 Loan and borrowings 1,435,400 1,435,400 — — 1,435,400 Derivative financial instruments 675,328 — 215,572 459,756 675,328 Total 5,237,942 4,562,614 215,572 459,756 5,237,942 Carrying amount Less than 3 months Between 3 months and 2 years 2 years and later Total December 31, 2017 Trade and other payables 1,200,820 1,200,820 — — 1,200,820 Accrued expenses 4,395,609 4,395,609 — — 4,395,609 Loan and borrowings 10,126,406 1,349,531 9,446,716 1,166,225 11,962,472 Derivative financial instruments 1,836,763 — — 1,836,763 1,836,763 Total 17,559,598 6,945,960 9,446,716 3,002,988 19,395,664
Disclosure of remaining contractual maturities of derivative financial liabilities	The table below analysis the remaining contractual maturities of financial liabilities, including estimated interest payments as of December 31, 2018 and 2017 . The amounts disclosed in the table are the undiscounted cash flows: Carrying amount Less than 3 months Between 3 months and 2 years 2 years and later Total December 31, 2018 Trade and other payables 1,836,335 1,836,335 — — 1,836,335 Accrued expenses 1,290,879 1,290,879 — — 1,290,879 Loan and borrowings 1,435,400 1,435,400 — — 1,435,400 Derivative financial instruments 675,328 — 215,572 459,756 675,328 Total 5,237,942 4,562,614 215,572 459,756 5,237,942 Carrying amount Less than 3 months Between 3 months and 2 years 2 years and later Total December 31, 2017 Trade and other payables 1,200,820 1,200,820 — — 1,200,820 Accrued expenses 4,395,609 4,395,609 — — 4,395,609 Loan and borrowings 10,126,406 1,349,531 9,446,716 1,166,225 11,962,472 Derivative financial instruments 1,836,763 — — 1,836,763 1,836,763 Total 17,559,598 6,945,960 9,446,716 3,002,988 19,395,664
Disclosure of fair value measurement of liabilities	Financial Fair values as at Fair value Valuation technique(s) and key input(s) December 31, December 31, Derivative financial liabilities Liability Liability Level 2 Black-Scholes option pricing model Derivative financial asset Asset Asset Level 3 The fair value is equal to the price paid to the counter party for obtaining the right under the purchase agreement. Subsequent, the fair value is adjusted proportionally for the part of the right consumed. Non-cash changes 01.01.2018 Financing 1) Fair Other 2) 31.12.2018 Derivative 1,836,763 188,636 (1,350,071 ) — 675,328 Loans 10,126,406 (9,272,328 ) — 581,322 1,435,400 Total 11,963,169 (9,083,692 ) (1,350,071 ) 581,322 2,110,728 Non-cash changes 01.01.2017 Financing 1) Fair Other 2) 31.12.2017 Derivative 117,132 5,091,817 (3,372,186 ) — 1,836,763 Loans 12,364,204 (2,087,076 ) — (150,722 ) 10,126,406 Total 12,481,336 3,004,741 (3,372,186 ) (150,722 ) 11,963,169 1) The financing cash flows are from loan repayment and from issuance of new derivative 2) IRR-Correction and FX-Difference
Disclosure of maximum exposure to credit risk	The Group’s maximum exposure to credit risk is represented by the carrying amount of each financial asset in the consolidated statement of financial position: December 31, 2018 December 31, 2017 Financial assets Cash and cash equivalents 5,393,207 14,973,369 Other receivables 80,040 79,840 Total 5,473,247 15,053,209
Disclosure of quantitative data about the exposure of financial assets and liabilities to currency risk	The summary of quantitative data about the exposure of the Group’s financial assets and liabilities to currency risk was as follows: 2018 2017 in CHF USD EUR USD EUR Cash and cash equivalents 3,618,778 208,507 13,901,698 116,942 Trade and other payables (1,646,910 ) (76,184 ) (365,999 ) (426,050 ) Accrued expenses (82,847 ) (370,145 ) (1,750,752 ) (1,692,946 ) Loan and borrowings (1,435,400 ) — (10,126,406 ) — Derivative financial instruments (675,328 ) — (1,836,763 ) — Net statement of financial position exposure -asset/(liability) (221,707 ) (237,822 ) (178,222 ) (2,002,054 )

Segment information (Tables)

Segment information (Tables)	12 Months Ended
	Dec. 31, 2018
Operating Segments [Abstract]
Disclosure of operating segments	The Group’s non-current assets by the Company’s country of domicile were as follows: December 31, 2018 December 31, 2017 Switzerland 3,812,001 1,958,709 Total 3,812,001 1,958,709

Property and equipment (Tables)

Property and equipment (Tables)	12 Months Ended
	Dec. 31, 2018
Property, plant and equipment [abstract]
Disclosure of detailed information about property, plant and equipment	The applicable estimated useful lives are as follows: Production equipment 5 years Office furniture and electronic data processing equipment (“EDP”) 3 years Leasehold improvements 5 years Production equipment Office furniture and EDP Leasehold improvements Total At cost As of January 1, 2017 283,499 233,706 236,462 753,667 Additions 6,389 — — 6,389 As of December 31, 2017 289,888 233,706 236,462 760,056 Additions — — — — Disposals — — (236,462 ) (236,462 ) As of December 31, 2018 289,888 233,706 — 523,594 Accumulated depreciation As of January 1, 2017 (184,329 ) (183,710 ) (16,334 ) (384,373 ) Charge for the year (53,594 ) (21,918 ) (47,272 ) (122,784 ) As of December 31, 2017 (237,923 ) (205,628 ) (63,606 ) (507,157 ) Charge for the year (32,485 ) (13,663 ) (26,565 ) (72,713 ) Disposals — — 90,171 90,171 As of December 31, 2018 (270,408 ) (219,291 ) — (489,699 ) Net book value As of December 31, 2017 51,965 28,078 172,856 252,899 As of December 31, 2018 19,480 14,415 — 33,895

Intangible assets (Tables)

Intangible assets (Tables)	12 Months Ended
	Dec. 31, 2018
Intangible Assets [Abstract]
Disclosure of detailed information about intangible assets [text block]	Licenses IP & Data rights Internally generated Total At cost As of January 1, 2017 1,482,520 — — 1,482,520 As of December 31, 2017 1,482,520 146,580 — 1,629,100 As of December 31, 2018 1,482,520 193,989 1,858,731 3,535,240 Accumulated amortization and impairment losses As of December 31, 2017 — — — — As of December 31, 2018 — — — — Net book value As of December 31, 2017 1,482,520 146,580 — 1,629,100 As of December 31, 2018 1,482,520 193,989 1,858,731 3,535,240

Other receivables (Tables)

Other receivables (Tables)	12 Months Ended
	Dec. 31, 2018
Trade and other receivables [abstract]
Disclosure of Other Receivables	December 31, 2018 December 31, 2017 Value added tax receivable 96,853 63,452 Withholding tax receivable 18,526 18,115 Deposit credit cards 80,040 79,840 Other 124,955 79,874 Total other receivables 320,374 241,281

Prepayments (Tables)

Prepayments (Tables)	12 Months Ended
	Dec. 31, 2018
Subclassifications of assets, liabilities and equities [abstract]
Disclosure of Prepayments	December 31, 2018 December 31, 2017 Advance payments to supplier 212,207 442,828 Insurance 139,076 200,246 Other — 9,839 Total prepayments 351,283 652,913

Cash and cash equivalents (Tabl

Cash and cash equivalents (Tables)	12 Months Ended
	Dec. 31, 2018
Subclassifications of assets, liabilities and equities [abstract]
Disclosure of Detailed Information for Cash and Cash Equivalents	December 31, 2018 December 31, 2017 Cash in bank accounts 5,392,599 14,972,761 Cash on hand 608 608 Total cash and cash equivalents 5,393,207 14,973,369

Capital and reserves (Tables)

Capital and reserves (Tables)	12 Months Ended
	Dec. 31, 2018
Share capital, reserves and other equity interest [Abstract]
Disclosure of issued share capital	The issued share capital of the Company at December 31 consisted of: December 31, 2018 December 31, 2017 Number CHF Number CHF Common shares with a nominal value of CHF 0.40 each — — 48,373,890 19,349,556 Common shares with a nominal value of CHF 0.02 each 35,516,785 710,336 — — Total 35,516,785 710,336 48,373,890 19,349,556 Common Shares (Number) 2018 2017 As of January 1 48,373,890 34,329,704 Common shares issued for the follow-on offering with a 12,800,000 14,044,186 nominal value of CHF 0.40 each Adjustment during the Merger: Issuance of Auris NewCo Shares 6,117,388 — Cancellation of Auris OldCo Shares (61,173,890 ) — Common shares issued for capital increase with a nominal value of CHF 0.02 each 29,399,397 — Total, as of December 31 35,516,785 48,373,890

Share based compensation (Table

Share based compensation (Tables)	12 Months Ended
	Dec. 31, 2018
Share-based payment arrangements [Abstract]
Disclosure of key terms and conditions related to grants	The key terms and conditions related to the grants under these programs are as at December 31, 2018 as follows: Plan Number of options outstanding Vesting conditions Contractual life of options Stock option Plan C 11,530 4 years' service from grant date 6 years Equity Incentive Plan Board 185,340 1 year service from grant date 8 years Equity Incentive Plan Employees / Board 405,280 2 years' service from grant date (50%) 8 years Equity Incentive Plan Employees / Board 390,627 3 years' service from grant date (50%) 8 years
Disclosure of the fair value of options measured based on the Black-Scholes formula	The fair value of the options was measured based on the Black-Scholes formula. Stock Option Plan Equity Incentive Equity Incentive Equity Incentive Equity Incentive Fair value at grant date USD 0.340 (1 year vesting) 1) USD 0.449 (2 year vesting) 1) USD 0.514 (3 year vesting) 1) USD 1.074 (1 year vesting) 2) USD 1.299 (2 year vesting) 2) USD 1.390 (3 year vesting) 2) USD 0.198 (1 year vesting) 1) USD 0.287 (2 year vesting) 1) USD 0.352 (3 year vesting) 1) USD 0.233 (1 year vesting) 2) USD 0.335 (2 year vesting) 2) USD 0.406 (3 year vesting) 2) Share price at grant date USD 0.64 USD 1.46 USD 0.76 USD 0.72 Exercise price USD 0.66 USD 1.58 USD 0.82 USD 0.82 Expected volatility 137.06% 93.38% 72.85% 93.01% Expected life 1,2 and 3 years 1,2 and 3 years 1,2 and 3 years 1,2 and 3 years Expected dividends — — — — Risk-free interest rate 3.06% 2.92% 2.38% 2.19% 1) October grants for the respective year 2) April grants for the respective year
Disclosure of the number and weighted average exercise prices of options	The number and weighted average exercise prices (in CHF) of options under the share option programs for Stock Option Plan A, Stock Option Plan C and the EIP are as follows: 2018 2017 Number of options Weighted average exercise price Weighted average remaining term Number of options Weighted average exercise price Weighted average remaining term Outstanding at January 1 225,154 17.40 6.88 1,038,140 3.36 6.14 Expired during the year (5,000 ) — — (67,500 ) — — Forfeited during the year (139,360 ) — — (637,200 ) — — Exercised during the year — — — — — — Granted during the year 911,983 1.04 7.73 1,918,100 0.82 7.70 Outstanding at December 31 992,777 1.10 7.45 2,251,540 1.74 6.88 Exercisable at December 31 63,314 26.28 5.08 326,510 4.48 4.24

Trade and other payables (Table

Trade and other payables (Tables)	12 Months Ended
	Dec. 31, 2018
Subclassifications of assets, liabilities and equities [abstract]
Components of trade and other payables	December 31, 2018 December 31, 2017 Trade accounts payable - third parties 1,810,445 1,032,557 Other 25,890 168,263 Total trade and other payables 1,836,335 1,200,820

Accrued expenses (Tables)

Accrued expenses (Tables)	12 Months Ended
	Dec. 31, 2018
Subclassifications of assets, liabilities and equities [abstract]
Components of accrued expenses	December 31, 2018 December 31, 2017 Accrued research and development costs including milestone payments 700,866 4,060,048 Professional fees 315,657 227,363 Accrued vacation & overtime 54,557 69,455 Employee benefits incl. share based payments 146,949 217,649 Other 72,850 108,198 Total accrued expenses 1,290,879 4,682,713

Research and development expe_2

Research and development expense (Tables)	12 Months Ended
	Dec. 31, 2018
Analysis of income and expense [abstract]
Components of research and development expense	December 31, 2018 December 31, 2017 December 31, 2016 Pre-clinical projects 873,453 642,821 546,429 Clinical projects 846,235 12,365,768 16,639,304 Drug manufacturing and substance 2,185,292 2,027,184 2,608,814 Employee benefits and expenses 1,652,791 2,773,516 2,854,624 Lease expenses 65,921 111,680 84,344 Patents and trademarks 634,986 603,892 941,836 Regulatory projects 398,426 632,387 1,043,287 Depreciation tangible assets 32,485 53,594 58,125 Total research and development expense 6,689,589 19,210,842 24,776,763

General and administrative ex_2

General and administrative expense (Tables)	12 Months Ended
	Dec. 31, 2018
Analysis of income and expense [abstract]
Components of general and administrative expense	December 31, 2018 December 31, 2017 December 31, 2016 Employee benefits and expenses 1,084,112 2,097,853 2,174,543 Business development 43,816 161,985 45,649 Travel expenses 70,944 199,484 158,774 Administration expenses 2,797,526 2,522,217 2,969,796 Lease expenses 52,416 81,277 63,695 Depreciation tangible assets 186,520 69,190 39,475 Capital tax expenses 29,200 18,403 (5,420 ) Total general and administrative expenses 4,264,534 5,150,409 5,446,512

Employee benefits (Tables)

Employee benefits (Tables)	12 Months Ended
	Dec. 31, 2018
Employee Benefits [Abstract]
Disclosure of defined benefit plan expense recognized in profit or loss	December 31, 2018 December 31, 2017 December 31, 2016 Salaries 2,542,952 3,761,171 3,662,180 Pension costs 108,978 378,588 342,805 Other social benefits 188,138 277,468 301,537 Share based payments costs 27,730 354,851 290,783 Recruitment costs — 125,731 391,035 Other personnel expenditures (130,895 ) (26,439 ) 40,827 Total employee benefits 2,736,903 4,871,370 5,029,167
Disclosure of net defined benefit liability (asset)	Change in fair value of plan assets 2018 2017 Fair value of plan assets at January 1 6,036,647 5,030,407 Interest income 36,304 37,500 Return on plan assets excluding interest income (634,190 ) 332,759 Employer contributions 146,245 236,074 Plan participants' contributions 146,245 236,074 Transfer-out amounts (3,367,834 ) (440,950 ) Transfer-in amounts of new employees 79,930 622,205 Administration expense (6,009 ) (17,422 ) Fair value of plan assets at December 31 2,437,338 6,036,647 Net defined benefit liability recognized in the statement of financial position December 31, 2018 December 31, 2017 Present value of funded defined benefit obligation 3,085,625 7,999,617 Fair value of plan assets (2,437,338 ) (6,036,647 ) Net defined benefit liability 648,287 1,962,970 Change in defined benefit obligation 2018 2017 Defined benefit obligation at January 1 7,999,617 7,122,841 Service costs 90,162 348,172 Plan participants' contribution 144,287 236,074 Interest cost 50,845 50,494 Actuarial losses (1,911,382 ) 60,781 Transfer-out amounts (3,367,834 ) (440,950 ) Transfer-in amounts of new employees 79,930 622,205 Defined benefit obligation at December 31 3,085,625 7,999,617
Disclosure of defined benefit plans	Defined Benefit Cost 2018 2017 2016 Service cost 90,162 348,172 319,173 Net interest expense 14,541 12,994 14,922 Administration expense 6,009 17,422 8,710 Total defined costs for the year recognized in profit or loss 110,712 378,588 342,805 Remeasurement of the Defined Benefit Liability 2018 2017 2016 Actuarial loss (gain) arising from changes in financial assumptions (119,117 ) (150,552 ) 412,396 Actuarial loss arising from experience adjustments (1,792,265 ) 211,331 264,417 Actuarial gain arising from demographic assumptions — — (258,876 ) Return on plan assets excluding interest income 634,190 (332,759 ) (23,835 ) Total defined benefit cost for the year recognized in the other comprehensive loss (1,277,192 ) (271,980 ) 394,102 Assumptions At December 31 2018 2017 2016 Discount rate 0.95 % 0.80 % 0.70 % Future salary increase 1.10 % 1.10 % 1.10 % Pension indexation 0.00 % 0.00 % 0.00 % Mortality and disability rates BVG2015G BVG2015G BVG 2015G
Disclosure of sensitivity analysis for actuarial assumptions	Sensitivity analysis Reasonably possible changes at the reporting date to one of the relevant actuarial assumptions, holding other assumptions constant, would have affected the defined benefit obligation by the amounts shown below. December 31, 2018 2017 Change in assumption 0.25 % increase 0.25 % increase Discount rate (138,606 ) (354,477 ) Salary increase 13,121 49,707 Pension indexation 65,943 189,965 Change in assumption + 1 year + 1 year Life expectancy 60,369 182,977

Finance income and finance ex_2

Finance income and finance expense (Tables)	12 Months Ended
	Dec. 31, 2018
Analysis of income and expense [abstract]
Components of finance income (cost)	2018 2017 2016 Interest income — 53,570 67,565 Net foreign currency exchange gain 1,103,067 1,912,681 843,950 Revaluation gain from derivative financial instruments 1,350,071 3,372,186 291,048 Total finance income 2,453,138 5,338,437 1,202,563 Interest expense (incl. Bank charges) 1,070,177 1,640,394 828,547 Net foreign currency exchange loss 1,242,938 2,737,273 944,047 Total finance expense 2,313,115 4,377,667 1,772,594 Finance income/(expense), net 140,023 960,770 (570,031 )

Taxation (Tables)

Taxation (Tables)	12 Months Ended
	Dec. 31, 2018
Income Taxes [Abstract]
Disclosure of income tax expense	The Group’s income tax expense recognized in the consolidated statement of profit or loss and other comprehensive loss was as follows: 2018 2017 2016 Deferred income tax expense (294,056 ) (21,415 ) — Deferred income tax gain 131,879 39,188 131,055 (162,177 ) 17,773 131,055
Disclosure of major components of tax expense (income)	The Group’s effective income tax expense differed from the expected theoretical amount computed by applying the Group’s applicable weighted average tax rate of 21.1% in 2018 ( 2017 : 21.7% , 2016 : 21.5% ) as summarized in the following table: Reconciliation 2018 2017 2016 Loss before income tax (11,334,224 ) (24,427,247 ) (30,793,306 ) Income tax at statutory tax rates applicable to results in the respective countries 2,397,177 5,311,030 6,629,237 Effect of unrecognized temporary differences 140,371 193,598 (27,072 ) Effect of unrecognized taxable losses (2,553,594 ) (5,429,935 ) (6,360,837 ) Effect of previously unrecognised deferred tax asset 114,116 39,189 131,055 Effect of expenses deductible for tax purposes — 9,696 2,505 Effect of expenses not considerable for tax purposes — — 23,716 Effect of impact from application of different tax rates (260,247 ) (105,805 ) (267,695 ) Effect of unrecognized taxable losses in equity — — 146 Income tax gain (162,177 ) 17,773 131,055
Disclosure of deferred taxes details	The tax effect of taxable temporary differences that give rise to deferred income tax liabilities or to deferred income tax assets as of December 31 is presented below: Deferred Tax Liabilities December 31, 2018 December 31, 2017 Intangible assets (627,540 ) (349,052 ) Hercules Loan Facility (889 ) (47,477 ) Derivative financial asset (17,763 ) — Total (646,192 ) (396,529 ) Deferred Tax Asset December 31, 2018 December 31, 2017 Net operating loss (NOL) 305,206 217,720 Total 305,206 217,720 Deferred Tax, net (340,986 ) (178,809 ) Deferred Tax 2018 Opening Balance Recognized in Profit or Loss Recognized in Equity Closing Balance Intangible assets (349,052 ) (276,293 ) (2,195 ) (627,540 ) Hercules Loan Facility (47,477 ) 46,588 — (889 ) Derivative financial asset — (17,763 ) — (17,763 ) Net operating loss (NOL) 217,720 85,291 2,195 305,206 Total (178,809 ) (162,177 ) — (340,986 ) Deferred Tax 2017 Opening Balance Recognized in Profit or Loss Recognized in Equity Closing Balance Intangible assets (327,637 ) (21,415 ) — (349,052 ) Hercules Loan Facility (76,390 ) 28,913 — (47,477 ) Net operating loss (NOL) 207,445 10,275 — 217,720 Total (196,582 ) 17,773 — (178,809 )
Disclosure of temporary difference, unused tax losses and unused tax credits	The Group’s tax loss carry-forwards with their expiry dates are as follows: December 31, 2018 December 31, 2017 Within 1 year 8,173,993 1,754,398 Between 1 and 3 years 41,980,704 31,089,191 Between 3 and 7 years 100,136,349 108,055,089 More than 7 years 1,070,993 1,072,260 Total 151,362,039 141,970,938 The tax effect of the major unrecognized temporary differences and loss carry-forwards is presented in the table below: December 31, 2018 December 31, 2017 Deductible temporary differences Employee benefit plan 143,271 433,816 Stock option plans 148,407 400,764 Total potential tax assets 291,678 834,580 Taxable unrecognized temporary differences Property and equipment — — Total unrecognized potential tax liabilities — — Offsetting potential tax liabilities with potential tax assets — — Net potential tax assets from temporary differences not recognized 291,678 834,580 Potential tax assets from loss carry-forwards not recognized 31,387,022 29,959,963 Total potential tax assets from loss carry-forwards and temporary differences not recognized 31,678,700 30,794,543

Loss per share (Tables)

Loss per share (Tables)	12 Months Ended
	Dec. 31, 2018
Earnings per share [abstract]
Disclosure of earnings per share	December 31, 2018 December 31, 2017 December 31, 2016 Loss attributable to owners of the Company (11,496,401 ) (24,409,474 ) (30,662,251 ) Weighted average number of shares outstanding * 15,900,865 4,374,187 3,432,928 Basic and diluted loss per share (0.72 ) (5.58 ) (8.93 ) * The basic and diluted loss per share for the year ended December 31, 2017 and the year ended December 31, 2016 is revised to reflect the reverse-split ratio of 10 to 1 following the Merger on March 13, 2018.

Commitments and contingencies (

Commitments and contingencies (Tables)	12 Months Ended
	Dec. 31, 2018
Leases1 [Abstract]
Disclosure of maturity analysis of operating lease payments	The future minimum lease payments under non-cancellable operating leases that are not accounted for in the statement of financial position were as follows: December 31, 2018 December 31, 2017 Within one year 24,374 161,110 Between one and five years — 446,051 Total 24,374 607,161

Related party transactions (Tab

Related party transactions (Tables)	12 Months Ended
	Dec. 31, 2018
Related Party [Abstract]
Disclosure of compensation of key management and Board of Directors	Executive Management Board of Directors Total 2018 2017 2016 2018 2017 2016 2018 2017 2016 Short term benefits 1,002,707 1,576,864 1,554,850 200,421 280,762 325,493 1,203,128 1,857,626 1,880,343 Post-employee benefits years 55,278 94,839 88,838 — — — 55,278 94,839 88,838 Share-based payment charge 204,224 190,659 217,981 60,657 72,647 103,380 264,881 263,306 321,361 Total 1,262,209 1,862,362 1,861,669 261,078 353,409 428,873 1,523,287 2,215,771 2,290,542

Reporting entity (Details)

Reporting entity (Details)	Mar. 13, 2018CHF (SFr)SFr / sharesshares	Dec. 31, 2018USD ($)shares	Dec. 31, 2018CHF (SFr)SFr / sharesshares	Dec. 31, 2018EUR (€)shares	Dec. 31, 2017CHF (SFr)SFr / sharesshares	Dec. 31, 2016shares
Disclosure of subsidiaries [line items]
Share capital			SFr 710,336		SFr 19,349,556
Number of shares outstanding | shares		35,516,785	35,516,785	35,516,785	48,373,890	34,329,704
Nominal value of common shares (in CHF per share) | SFr / shares			SFr 0.02		SFr 0.40
Reverse stock split, conversion ratio, number of original shares held for 1 share in Auris NewCo	10
Auris Medical AG [Member]
Disclosure of subsidiaries [line items]
Proportion of ownership interest in subsidiary (as a percent)		100.00%
Nominal share capital			SFr 2,500,000
Otolanum AG [Member]
Disclosure of subsidiaries [line items]
Proportion of ownership interest in subsidiary (as a percent)		100.00%
Nominal share capital			SFr 100,000
Auris Medical Inc. [Member]
Disclosure of subsidiaries [line items]
Proportion of ownership interest in subsidiary (as a percent)		100.00%
Nominal share capital | $		$ 15,000
Auris Medical Ltd. [Member]
Disclosure of subsidiaries [line items]
Proportion of ownership interest in subsidiary (as a percent)		100.00%
Nominal share capital | €				€ 100
Auris Medical NewCo Holding AG
Disclosure of subsidiaries [line items]
Share capital	SFr 122,347.76
Number of shares outstanding | shares	6,117,388
Nominal value of common shares (in CHF per share) | SFr / shares	SFr 0.02
Reverse stock split, conversion ratio, number of original shares held for 1 share in Auris NewCo	10

Basis of preparation (Details)

Basis of preparation (Details) - CHF (SFr)	Dec. 31, 2018	Dec. 31, 2017
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deferred tax assets	SFr 305,206	SFr 217,720
Net operating loss (NOL)
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deferred tax assets	SFr 305,206	SFr 217,720

Significant accounting polici_4

Significant accounting policies - Segment reporting (Narrative) (Details)	12 Months Ended
	Dec. 31, 2018segment
Corporate Information and Statement of IFRS Compliance [Abstract]
Number of operating segments	1

Significant accounting polici_5

Significant accounting policies - Disclosure of closing and average exchange rates for the most significant foreign currencies (Details)	12 Months Ended
	Dec. 31, 2018SFr / $SFr / €entity	Dec. 31, 2017SFr / $SFr / €	Dec. 31, 2016SFr / $SFr / €
Switzerland
Disclosure of geographical areas [line items]
Reporting entities	3
Closing rate	1	1	1
Average exchange rate	1	1	1
United States
Disclosure of geographical areas [line items]
Reporting entities	1
Closing rate | SFr / $	0.9827	0.9725	1.0196
Average exchange rate | SFr / $	0.9768	0.9849	0.9855
Europe
Disclosure of geographical areas [line items]
Reporting entities	1
Closing rate | SFr / €	1.1283	1.1713	1.0723
Average exchange rate | SFr / €	1.1573	1.1116	1.0901

Significant accounting polici_6

Significant accounting policies - Disclosure of applicable estimated useful lives (Details)	12 Months Ended
	Dec. 31, 2018
Production equipment
Disclosure of detailed information about property, plant and equipment [line items]
Useful life	5 years
Office furniture and electronic data processing equipment (“EDP”)
Disclosure of detailed information about property, plant and equipment [line items]
Useful life	3 years
Leasehold improvements
Disclosure of detailed information about property, plant and equipment [line items]
Useful life	5 years

Significant accounting polici_7

Significant accounting policies - Intangible assets (Narrative) (Details)	12 Months Ended
	Dec. 31, 2018
Licenses
Disclosure of detailed information about intangible assets [line items]
Estimated useful life	10 years

Significant accounting polici_8

Significant accounting policies - Share-based compensation (Narrative) (Details)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Stock Option Plan A
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting period	3 years
Stock Option Plan C
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting period	4 years
Tranche 1 | Equity Incentive Plan
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting period	2 years
Vesting percentage	50.00%
Tranche 2 | Equity Incentive Plan
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting period	3 years
Vesting percentage	50.00%
Board of Directors
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting period	1 year	1 year

Financial instruments and ris_3

Financial instruments and risk management - Disclosure of the carrying amounts of financial assets and liabilities (Details) - CHF (SFr)	Dec. 31, 2018	Dec. 31, 2017
Disclosure Of Financial Assets And Liabilities [Line Items]
Financial assets	SFr 5,473,247	SFr 15,053,209
Financial liabilities	5,237,942	17,559,598
Trade and other payables | At amortized cost
Disclosure Of Financial Assets And Liabilities [Line Items]
Financial liabilities	1,836,335	1,200,820
Accrued expenses | At amortized cost
Disclosure Of Financial Assets And Liabilities [Line Items]
Financial liabilities	1,290,879	4,395,609
Loan | At amortized cost
Disclosure Of Financial Assets And Liabilities [Line Items]
Financial liabilities	1,435,400	10,126,406
Derivative financial instruments | At fair value through profit and loss
Disclosure Of Financial Assets And Liabilities [Line Items]
Financial liabilities	675,328	1,836,763
Cash and cash equivalents
Disclosure Of Financial Assets And Liabilities [Line Items]
Financial assets	5,393,207	14,973,369
Other receivables
Disclosure Of Financial Assets And Liabilities [Line Items]
Financial assets	SFr 80,040	SFr 79,840

Financial instruments and ris_4

Financial instruments and risk management - Disclosure of remaining contractual maturities of financial liabilities (Details) - CHF (SFr)	Dec. 31, 2018	Dec. 31, 2017
Disclosure Of Financial Assets And Liabilities [Line Items]
Non-derivative financial liabilities, undiscounted cash flows		SFr 19,395,664
Total	SFr 5,237,942
Less than 3 months
Disclosure Of Financial Assets And Liabilities [Line Items]
Non-derivative financial liabilities, undiscounted cash flows		6,945,960
Total	4,562,614
Between 3 months and 2 years
Disclosure Of Financial Assets And Liabilities [Line Items]
Non-derivative financial liabilities, undiscounted cash flows		9,446,716
Total	215,572
2 years and later
Disclosure Of Financial Assets And Liabilities [Line Items]
Non-derivative financial liabilities, undiscounted cash flows		3,002,988
Total	459,756
Trade and other payables
Disclosure Of Financial Assets And Liabilities [Line Items]
Non-derivative financial liabilities, undiscounted cash flows	1,836,335	1,200,820
Trade and other payables | Less than 3 months
Disclosure Of Financial Assets And Liabilities [Line Items]
Non-derivative financial liabilities, undiscounted cash flows	1,836,335	1,200,820
Trade and other payables | Between 3 months and 2 years
Disclosure Of Financial Assets And Liabilities [Line Items]
Non-derivative financial liabilities, undiscounted cash flows	0	0
Trade and other payables | 2 years and later
Disclosure Of Financial Assets And Liabilities [Line Items]
Non-derivative financial liabilities, undiscounted cash flows	0	0
Accrued expenses
Disclosure Of Financial Assets And Liabilities [Line Items]
Non-derivative financial liabilities, undiscounted cash flows	1,290,879	4,395,609
Accrued expenses | Less than 3 months
Disclosure Of Financial Assets And Liabilities [Line Items]
Non-derivative financial liabilities, undiscounted cash flows	1,290,879	4,395,609
Accrued expenses | Between 3 months and 2 years
Disclosure Of Financial Assets And Liabilities [Line Items]
Non-derivative financial liabilities, undiscounted cash flows	0	0
Accrued expenses | 2 years and later
Disclosure Of Financial Assets And Liabilities [Line Items]
Non-derivative financial liabilities, undiscounted cash flows	0	0
Loan and borrowings
Disclosure Of Financial Assets And Liabilities [Line Items]
Non-derivative financial liabilities, undiscounted cash flows	1,435,400	11,962,472
Loan and borrowings | Less than 3 months
Disclosure Of Financial Assets And Liabilities [Line Items]
Non-derivative financial liabilities, undiscounted cash flows	1,435,400	1,349,531
Loan and borrowings | Between 3 months and 2 years
Disclosure Of Financial Assets And Liabilities [Line Items]
Non-derivative financial liabilities, undiscounted cash flows	0	9,446,716
Loan and borrowings | 2 years and later
Disclosure Of Financial Assets And Liabilities [Line Items]
Non-derivative financial liabilities, undiscounted cash flows	0	1,166,225
Derivative financial instruments
Disclosure Of Financial Assets And Liabilities [Line Items]
Derivative financial liabilities, undiscounted cash flows	675,328	1,836,763
Derivative financial instruments | Less than 3 months
Disclosure Of Financial Assets And Liabilities [Line Items]
Derivative financial liabilities, undiscounted cash flows	0	0
Derivative financial instruments | Between 3 months and 2 years
Disclosure Of Financial Assets And Liabilities [Line Items]
Derivative financial liabilities, undiscounted cash flows	215,572	0
Derivative financial instruments | 2 years and later
Disclosure Of Financial Assets And Liabilities [Line Items]
Derivative financial liabilities, undiscounted cash flows	459,756	1,836,763
Carrying amount
Disclosure Of Financial Assets And Liabilities [Line Items]
Non-derivative financial liabilities, undiscounted cash flows		17,559,598
Total	5,237,942
Carrying amount | Trade and other payables
Disclosure Of Financial Assets And Liabilities [Line Items]
Non-derivative financial liabilities, undiscounted cash flows	1,836,335	1,200,820
Carrying amount | Accrued expenses
Disclosure Of Financial Assets And Liabilities [Line Items]
Non-derivative financial liabilities, undiscounted cash flows	1,290,879	4,395,609
Carrying amount | Loan and borrowings
Disclosure Of Financial Assets And Liabilities [Line Items]
Non-derivative financial liabilities, undiscounted cash flows	1,435,400	10,126,406
Carrying amount | Derivative financial instruments
Disclosure Of Financial Assets And Liabilities [Line Items]
Derivative financial liabilities, undiscounted cash flows	SFr 675,328	SFr 1,836,763

Financial instruments and ris_5

Financial instruments and risk management - Disclosure of fair value of derivative liabilities (Details) - CHF (SFr)	Dec. 31, 2018	Dec. 31, 2017
Disclosure of fair value measurement of liabilities [line items]
Financial liabilities	SFr 5,237,942	SFr 17,559,598
Financial assets	5,473,247	15,053,209
Level 2 | Derivative financial instruments
Disclosure of fair value measurement of liabilities [line items]
Financial liabilities	675,328	SFr 1,836,763
Level 3 | Derivative financial instruments
Disclosure of fair value measurement of liabilities [line items]
Financial assets	SFr 226,865

Financial instruments and ris_6

Financial instruments and risk management - Reconciliation of changes in fair value measurement, liabilities (Details) - CHF (SFr)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Reconciliation of changes in fair value measurement, liabilities [abstract]
Beginning Balance	SFr 19,988,481
Ending Balance	6,227,215	SFr 19,988,481
At fair value
Reconciliation of changes in fair value measurement, liabilities [abstract]
Beginning Balance	11,963,169	12,481,336
Financing cash flows	(9,083,692)	3,004,741
Fair value revaluation	(1,350,071)	(3,372,186)
Other changes	581,322	(150,722)
Ending Balance	2,110,728	11,963,169
At fair value | Derivative financial instruments
Reconciliation of changes in fair value measurement, liabilities [abstract]
Beginning Balance	1,836,763	117,132
Financing cash flows	188,636	5,091,817
Fair value revaluation	(1,350,071)	(3,372,186)
Other changes	0	0
Ending Balance	675,328	1,836,763
At fair value | Loans
Reconciliation of changes in fair value measurement, liabilities [abstract]
Beginning Balance	10,126,406	12,364,204
Financing cash flows	(9,272,328)	(2,087,076)
Fair value revaluation	0	0
Other changes	581,322	(150,722)
Ending Balance	SFr 1,435,400	SFr 10,126,406

Financial instruments and ris_7

Financial instruments and risk management - Disclosure of maximum exposure to credit risk (Details) - Credit risk [member] - CHF (SFr)	Dec. 31, 2018	Dec. 31, 2017
Disclosure of credit risk exposure [line items]
Maximum exposure to credit risk	SFr 5,473,247	SFr 15,053,209
Cash and cash equivalents
Disclosure of credit risk exposure [line items]
Maximum exposure to credit risk	5,393,207	14,973,369
Other receivables
Disclosure of credit risk exposure [line items]
Maximum exposure to credit risk	SFr 80,040	SFr 79,840

Financial instruments and ris_8

Financial instruments and risk management - Disclosure of quantitative data about the exposure of financial assets and liabilities to currency risk (Details) - Currency risk - CHF (SFr)	Dec. 31, 2018	Dec. 31, 2017
USD
Disclosure of nature and extent of risks arising from financial instruments [line items]
Net statement of financial position exposure -asset/(liability)	SFr (221,707)	SFr (178,222)
EUR
Disclosure of nature and extent of risks arising from financial instruments [line items]
Net statement of financial position exposure -asset/(liability)	(237,822)	(2,002,054)
Cash and cash equivalents | USD
Disclosure of nature and extent of risks arising from financial instruments [line items]
Net statement of financial position exposure -asset/(liability)	3,618,778	13,901,698
Cash and cash equivalents | EUR
Disclosure of nature and extent of risks arising from financial instruments [line items]
Net statement of financial position exposure -asset/(liability)	208,507	116,942
Trade and other payables | USD
Disclosure of nature and extent of risks arising from financial instruments [line items]
Net statement of financial position exposure -asset/(liability)	(1,646,910)	(365,999)
Trade and other payables | EUR
Disclosure of nature and extent of risks arising from financial instruments [line items]
Net statement of financial position exposure -asset/(liability)	(76,184)	(426,050)
Accrued expenses | USD
Disclosure of nature and extent of risks arising from financial instruments [line items]
Net statement of financial position exposure -asset/(liability)	(82,847)	(1,750,752)
Accrued expenses | EUR
Disclosure of nature and extent of risks arising from financial instruments [line items]
Net statement of financial position exposure -asset/(liability)	(370,145)	(1,692,946)
Loan and borrowings | USD
Disclosure of nature and extent of risks arising from financial instruments [line items]
Net statement of financial position exposure -asset/(liability)	(1,435,400)	(10,126,406)
Loan and borrowings | EUR
Disclosure of nature and extent of risks arising from financial instruments [line items]
Net statement of financial position exposure -asset/(liability)	0	0
Derivative financial instruments | USD
Disclosure of nature and extent of risks arising from financial instruments [line items]
Net statement of financial position exposure -asset/(liability)	(675,328)	(1,836,763)
Derivative financial instruments | EUR
Disclosure of nature and extent of risks arising from financial instruments [line items]
Net statement of financial position exposure -asset/(liability)	SFr 0	SFr 0

Financial instruments and ris_9

Financial instruments and risk management - Narrative (Details)	12 Months Ended
	Dec. 31, 2018CHF (SFr)	Dec. 31, 2017CHF (SFr)	Jul. 19, 2016USD ($)
Interest rate risk
Disclosure of nature and extent of risks arising from financial instruments [line items]
Increase or decrease in rate (as a percent)	0.50%
Impact of increase or decrease in rate on net result	SFr 3,721	SFr 62,500
USD | Currency risk
Disclosure of nature and extent of risks arising from financial instruments [line items]
Increase or decrease in rate (as a percent)	5.00%
Impact of increase or decrease in rate on net result	SFr 10,886	8,662
EUR | Currency risk
Disclosure of nature and extent of risks arising from financial instruments [line items]
Increase or decrease in rate (as a percent)	5.00%
Impact of increase or decrease in rate on net result	SFr 13,413	SFr 117,320
Secured term loan facility
Disclosure of nature and extent of risks arising from financial instruments [line items]
Term loan facility (up to) | $			$ 20,000,000
Drawn on term loan facility	SFr 1,435,400		$ 12,500,000
Minimum | Floating interest rate | Secured term loan facility
Disclosure of nature and extent of risks arising from financial instruments [line items]
Interest rate per annum (as a percent)			9.55%

Segment information (Details)

Segment information (Details) - CHF (SFr)	Dec. 31, 2018	Dec. 31, 2017
Disclosure of operating segments [line items]
Non-current assets	SFr 3,812,001	SFr 1,958,709
Switzerland
Disclosure of operating segments [line items]
Non-current assets	SFr 3,812,001	SFr 1,958,709

Property and equipment (Details

Property and equipment (Details) - CHF (SFr)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Reconciliation of changes in property, plant and equipment [abstract]
Property, plant and equipment	SFr 252,899
Disposals	(236,462)
Property, plant and equipment	33,895	SFr 252,899
At cost
Reconciliation of changes in property, plant and equipment [abstract]
Property, plant and equipment	760,056	753,667
Additions	0	6,389
Property, plant and equipment	523,594	760,056
Accumulated depreciation
Reconciliation of changes in property, plant and equipment [abstract]
Property, plant and equipment	(507,157)	(384,373)
Additions	(72,713)	(122,784)
Disposals	90,171
Property, plant and equipment	(489,699)	(507,157)
Production equipment
Reconciliation of changes in property, plant and equipment [abstract]
Property, plant and equipment	51,965
Property, plant and equipment	19,480	51,965
Production equipment | At cost
Reconciliation of changes in property, plant and equipment [abstract]
Property, plant and equipment	289,888	283,499
Additions	0	6,389
Disposals	0
Property, plant and equipment	289,888	289,888
Production equipment | Accumulated depreciation
Reconciliation of changes in property, plant and equipment [abstract]
Property, plant and equipment	(237,923)	(184,329)
Additions	(32,485)	(53,594)
Disposals	0
Property, plant and equipment	(270,408)	(237,923)
Office furniture and EDP
Reconciliation of changes in property, plant and equipment [abstract]
Property, plant and equipment	28,078
Property, plant and equipment	14,415	28,078
Office furniture and EDP | At cost
Reconciliation of changes in property, plant and equipment [abstract]
Property, plant and equipment	233,706	233,706
Additions	0	0
Disposals	0
Property, plant and equipment	233,706	233,706
Office furniture and EDP | Accumulated depreciation
Reconciliation of changes in property, plant and equipment [abstract]
Property, plant and equipment	(205,628)	(183,710)
Additions	(13,663)	(21,918)
Disposals	0
Property, plant and equipment	(219,291)	(205,628)
Leasehold improvements
Reconciliation of changes in property, plant and equipment [abstract]
Property, plant and equipment	172,856
Property, plant and equipment	0	172,856
Leasehold improvements | At cost
Reconciliation of changes in property, plant and equipment [abstract]
Property, plant and equipment	236,462	236,462
Additions	0	0
Disposals	(236,462)
Property, plant and equipment	0	236,462
Leasehold improvements | Accumulated depreciation
Reconciliation of changes in property, plant and equipment [abstract]
Property, plant and equipment	(63,606)	(16,334)
Additions	(26,565)	(47,272)
Disposals	90,171
Property, plant and equipment	SFr 0	SFr (63,606)

Intangible assets (Details)

Intangible assets (Details) - CHF (SFr)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2013	Dec. 06, 2018	Jul. 30, 2017	Dec. 31, 2016
Disclosure of detailed information about intangible assets [line items]
Intangible assets	SFr 3,535,240	SFr 1,629,100
Amortization expense	0	0
Impairment loss	0	0
At cost
Disclosure of detailed information about intangible assets [line items]
Intangible assets	3,535,240	1,629,100				SFr 1,482,520
Accumulated amortization
Disclosure of detailed information about intangible assets [line items]
Intangible assets	0	0
Licenses
Disclosure of detailed information about intangible assets [line items]
Intangible assets	1,482,520	1,482,520
Licenses | At cost
Disclosure of detailed information about intangible assets [line items]
Intangible assets	1,482,520	1,482,520				1,482,520
Milestone payment intangible			SFr 1,125,000
Licenses | Accumulated amortization
Disclosure of detailed information about intangible assets [line items]
Intangible assets	0	0
IP & Data rights
Disclosure of detailed information about intangible assets [line items]
Intangible assets	193,989	146,580		SFr 47,409
IP & Data rights | At cost
Disclosure of detailed information about intangible assets [line items]
Intangible assets	193,989	146,580			SFr 146,580	0
IP & Data rights | Accumulated amortization
Disclosure of detailed information about intangible assets [line items]
Intangible assets	0	0
Internally generated
Disclosure of detailed information about intangible assets [line items]
Intangible assets	1,858,731	0
Increase (decrease) through other changes, intangible assets other than goodwill	1,858,731
Internally generated | At cost
Disclosure of detailed information about intangible assets [line items]
Intangible assets	1,858,731	0				SFr 0
Internally generated | Accumulated amortization
Disclosure of detailed information about intangible assets [line items]
Intangible assets	SFr 0	SFr 0

Other receivables (Details)

Other receivables (Details) - CHF (SFr)	Dec. 31, 2018	Dec. 31, 2017
Trade and other receivables [abstract]
Value added tax receivable	SFr 96,853	SFr 63,452
Withholding tax receivable	18,526	18,115
Deposit credit cards	80,040	79,840
Other	124,955	79,874
Total other receivables	SFr 320,374	SFr 241,281

Prepayments (Details)

Prepayments (Details) - CHF (SFr)	Dec. 31, 2018	Dec. 31, 2017
Subclassifications of assets, liabilities and equities [abstract]
Advance payments to supplier	SFr 212,207	SFr 442,828
Insurance	139,076	200,246
Other	0	9,839
Total prepayments	SFr 351,283	SFr 652,913

Cash and cash equivalents (Deta

Cash and cash equivalents (Details) - CHF (SFr)	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Subclassifications of assets, liabilities and equities [abstract]
Cash in bank accounts	SFr 5,392,599	SFr 14,972,761
Cash on hand	608	608
Total cash and cash equivalents	SFr 5,393,207	SFr 14,973,369	SFr 32,442,222	SFr 50,237,300

Capital and reserves - Disclosu

Capital and reserves - Disclosure of issued share capital (Details) - CHF (SFr)	Jul. 17, 2018	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disclosure of classes of share capital [line items]
Nominal value of common shares (in CHF per share)		SFr 0.02	SFr 0.40
Value (CHF)		SFr 710,336	SFr 19,349,556
Reconciliation of number of shares outstanding [abstract]
Beginning balance (in shares)		48,373,890	34,329,704
Ending balance (in shares)		35,516,785	48,373,890
Common shares issued for the follow-on offering
Reconciliation of number of shares outstanding [abstract]
Common shares issued (in shares)		12,800,000	14,044,186
Common shares nominal value
Disclosure of classes of share capital [line items]
Nominal value of common shares (in CHF per share)		SFr 0.02	SFr 0.40	SFr 0.40
Number (in shares)		35,516,785	48,373,890
Value (CHF)		SFr 710,336	SFr 19,349,556
Reconciliation of number of shares outstanding [abstract]
Beginning balance (in shares)		19,349,556
Ending balance (in shares)	742,833	710,335.70	19,349,556
Common shares nominal value | Common shares issued for the follow-on offering
Disclosure of classes of share capital [line items]
Nominal value of common shares (in CHF per share)			SFr 0.40	SFr 0.40
Common shares nominal value | Issuance of Auris NewCo Shares
Reconciliation of number of shares outstanding [abstract]
Common shares issued (in shares)		6,117,388
Common shares nominal value | Cancellation of Auris OldCo Shares
Reconciliation of number of shares outstanding [abstract]
Common shares issued (in shares)		(61,173,890)
Common shares nominal value | Common shares issued for capital increase with a nominal value of CHF 0.02 each
Reconciliation of number of shares outstanding [abstract]
Common shares issued (in shares)		29,399,397

Capital and reserves - Follow-O

Capital and reserves - Follow-On Offering on Nasdaq Global Market (Narrative) (Details)

Nov. 30, 2018CHF (SFr)

Jul. 17, 2018CHF (SFr)SFr / sharesshares

May 02, 2018USD ($)

Mar. 13, 2018CHF (SFr)SFr / sharesshares

Jan. 30, 2018CHF (SFr)SFr / sharesshares

Oct. 16, 2017USD ($)shares

Oct. 16, 2017CHF (SFr)shares

Oct. 10, 2017USD ($)shares

Oct. 10, 2017CHF (SFr)

Feb. 21, 2017USD ($)

Feb. 21, 2017CHF (SFr)SFr / sharesshares

Dec. 31, 2018USD ($)

Dec. 31, 2018CHF (SFr)SFr / sharesshares

Dec. 31, 2018CHF (SFr)SFr / sharesshares

Dec. 31, 2017CHF (SFr)SFr / sharesshares

Dec. 31, 2016CHF (SFr)SFr / sharesshares

Disclosure of classes of share capital [line items]

Nominal value (in CHF per share) | SFr / shares

SFr 0.02

SFr 0.02

SFr 0.40

Common shares outstanding (in shares) | shares

35,516,785

35,516,785

48,373,890

34,329,704

Adjustments of transaction costs

SFr 851,692

Finance costs

SFr 2,313,115

SFr 4,377,667

SFr 1,772,594

Transaction costs recognized in equity

1,259,587

521,515

Transaction costs recognized in profit or loss

520,125

SFr 1,026,766

0

Share issue related cost

SFr 1,862

Commitment Purchase Agreement

Disclosure of classes of share capital [line items]

Purchase common shares fair value | $

$ 10,000,000

Agreement term

30 months

2017 Commitment Purchas Agreement

Disclosure of classes of share capital [line items]

Maximum subscribe of common shares

SFr 13,500,000

Number of shares issued (in shares) | shares

2,600,000

2,600,000

Proceeds from issue of ordinary shares

SFr 1,700,000

2018 Commitment Purchase Agreement

Disclosure of classes of share capital [line items]

Common shares issued (in shares) | shares

1,750,000

Proceeds from issue of ordinary shares

SFr 1,000,000

Transaction costs

349,907

Non-current derivative financial assets

SFr 252,351

252,351

Finance costs

SFr 97,556

Public offering

Disclosure of classes of share capital [line items]

Gross proceeds

$ 10,000,000

SFr 9,998,305

Transaction costs recognized in equity

397,685

Transaction costs recognized in profit or loss

SFr 506,234

Conversion ratio

0.70

0.70

Share issue related cost

SFr 903,919

Ordinary shares

Disclosure of classes of share capital [line items]

Nominal value (in CHF per share) | SFr / shares

SFr 0.02

SFr 0.02

SFr 0.40

SFr 0.40

Common shares outstanding (in shares) | shares

742,833

710,335.70

710,335.70

19,349,556

Number of shares issued (in shares) | shares

35,516,785

35,516,785

48,373,890

Ordinary shares | A.G.P Sales Agreement

Disclosure of classes of share capital [line items]

Maximum subscribe of common shares

SFr 25,000,000

Number of shares issued (in shares) | shares

2,595,814

2,595,814

Gross proceeds | $

$ 1,300,000

Ordinary shares | Common Shares [Member]

Disclosure of classes of share capital [line items]

Number of shares issued (in shares) | shares

616,740

616,740

Gross proceeds

SFr 350,486

Ordinary shares | FiveT Capital AG

Disclosure of classes of share capital [line items]

Gross proceeds

SFr 1,600,000

Common shares issued (in shares) | shares

3,315,000

Ordinary shares | Commitment Purchase Agreement

Disclosure of classes of share capital [line items]

Number of shares issued (in shares) | shares

1,744,186

1,744,186

2,300,000

Gross proceeds

$ 1,500,000

SFr 1,446,150

$ 1,630,415

SFr 1,594,611

Agreement term

30 months

30 months

Share subscription agreement, subscription amount | $

$ 13,500,000

Transaction costs recognized in equity

SFr 63,056

SFr 25,701

Transaction costs recognized in profit or loss

265,205

Commitment fee

$ 300,000

290,400

Commitment fee related to cash proceeds from issue of shares

35,073

Derecognition of commitment fee

SFr 255,327

Ordinary shares | Public offering

Disclosure of classes of share capital [line items]

Nominal value (in CHF per share) | SFr / shares

SFr 0.40

Number of shares issued (in shares) | shares

10,000,000

Gross proceeds

SFr 4,906,488

Series A Warrants

Disclosure of classes of share capital [line items]

Nominal value (in CHF per share) | SFr / shares

SFr 0.02

Number of shares issued (in shares) | shares

6,282,051

Gross proceeds

SFr 1,132,762

Common shares issued (in shares) | shares

17,948,717

2,904,518

Nominal value per share (in CHF per share) | SFr / shares

SFr 0.35

Series B Warrants

Disclosure of classes of share capital [line items]

Number of shares issued (in shares) | shares

4,487,178

Gross proceeds

SFr 1,117,125

Common shares issued (in shares) | shares

2,864,422

Nominal value per share (in CHF per share) | SFr / shares

SFr 0.25

Warrants

Disclosure of classes of share capital [line items]

Nominal value (in CHF per share) | SFr / shares

SFr 0.39

Common shares outstanding (in shares) | shares

108,809

Equity Offerings

Disclosure of classes of share capital [line items]

Gross proceeds

SFr 6,200,000

Warrants

Disclosure of classes of share capital [line items]

Nominal value per share (in CHF per share) | SFr / shares

SFr 0.40

Proceeds from issue of ordinary shares

SFr 4,500,000

Transaction costs

SFr 654,985

Finance costs

SFr 313,760

Issuance initial public offering (in shares) | shares

12,499,999

Warrants outstanding (in shares) | shares

7,499,999

Number of common shares exercisable through warrants, up to (in shares) | shares

750,002

Exercise price of warrants (in CHF per share) | SFr / shares

SFr 5

Issuance of common shares, transaction costs

SFr 341,226

Warrants | Public offering

Disclosure of classes of share capital [line items]

Number of shares issued (in shares) | shares

10,000,000

Gross proceeds

SFr 5,091,817

Capital and reserves - Issuance

Capital and reserves - Issuance of common shares with restrictions (Narrative) (Details) - CHF (SFr)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Jul. 17, 2018	Jan. 07, 2016
Disclosure of classes of share capital [line items]
Nominal value (in CHF per share)	SFr 0.02	SFr 0.40
Payroll charge	SFr 27,730	SFr 354,851	SFr 290,783
Common shares outstanding (in shares)	35,516,785	48,373,890	34,329,704
Common shares nominal value
Disclosure of classes of share capital [line items]
Shares awarded and issued (in shares)	35,516,785	48,373,890
Nominal value (in CHF per share)	SFr 0.02	SFr 0.40	SFr 0.40
Common shares outstanding (in shares)	710,335.70	19,349,556		742,833
Restricted common shares | Equity Incentive Plan | Common shares nominal value
Disclosure of classes of share capital [line items]
Shares awarded and issued (in shares)					25,813
Nominal value (in CHF per share)					SFr 0.40
Payroll charge		SFr 188,092

Capital and reserves - Controll

Capital and reserves - Controlled Equity Offering (Narrative) (Details) - SFr / shares	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disclosure of classes of share capital [line items]
Nominal value (in CHF per share)	SFr 0.02	SFr 0.40
Common shares nominal value
Disclosure of classes of share capital [line items]
Nominal value (in CHF per share)	SFr 0.02	SFr 0.40	SFr 0.40

Capital and reserves - Authoriz

Capital and reserves - Authorized share capital (Narrative) (Details) - CHF (SFr)	Dec. 31, 2018	Dec. 31, 2017
Disclosure of classes of share capital [line items]
Authorized capital	SFr 22,580.26
Nominal value (in CHF per share)	SFr 0.02	SFr 0.40
Board of Directors
Disclosure of classes of share capital [line items]
Registered shares (in shares)	1,129,013

Capital and reserves - Conditio

Capital and reserves - Conditional share capital (Narrative) (Details) - CHF (SFr)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Disclosure of classes of share capital [line items]
Nominal value (in CHF per share)	SFr 0.02	SFr 0.40
Execution of subscription rights
Disclosure of classes of share capital [line items]
Issuance of fully paid registered Common Shares that may increase share capital (up to) (in shares)	1,630,613
Nominal value (in CHF per share)	SFr 0.02
Maximum amount	SFr 32,612.26
Execution of conversion rights in connection with warrants and convertible bondsexecution of conversion rights in connection with warrants and convertible bonds
Disclosure of classes of share capital [line items]
Issuance of fully paid registered Common Shares that may increase share capital (up to) (in shares)	11,771,002
Nominal value (in CHF per share)	SFr 0.02
Maximum amount	SFr 235,420.04

Share based compensation - Desc

Share based compensation - Description (Narrative) (Details)	12 Months Ended
	Dec. 31, 2018CHF (SFr)shares	Dec. 31, 2017CHF (SFr)shares	Dec. 31, 2016CHF (SFr)shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Total expense recognized for equity-settled share-based payment transactions | SFr	SFr 42,757	SFr 354,851	SFr 290,783
Share based payments costs | SFr	SFr 27,730	SFr 354,851	SFr 290,783
Number of share options granted (in shares) | shares	911,983
Stock Option Plan C
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting period	4 years
Stock Option Plan B
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of share options granted (in shares) | shares			0
Equity Incentive Plan
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of share options granted (in shares) | shares	911,983	1,918,100
Period preceding the date of grant for the Board of Directors to define the exercise price	30 days
Options | Stock Option Plan A
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting period	3 years
Options | Stock Option Plan C
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting period	4 years
Intangible assets
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share based payments costs | SFr	SFr 15,027

Share based compensation - Disc

Share based compensation - Disclosure of key terms and conditions related to grants (Details) - shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number of options outstanding (in shares)	992,777	225,154
Stock option Plan C
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number of options outstanding (in shares)	11,530
Vesting period	4 years
Contractual life of options	6 years
Tranche 1 | Equity Incentive Plan
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Vesting percentage	50.00%
Tranche 2 | Equity Incentive Plan
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Vesting percentage	50.00%
Board | Equity Incentive Plan
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number of options outstanding (in shares)	185,340
Vesting period	1 year
Contractual life of options	8 years
Employees/Board | Tranche 1 | Equity Incentive Plan
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number of options outstanding (in shares)	405,280
Vesting period	2 years
Vesting percentage	50.00%
Contractual life of options	8 years
Employees/Board | Tranche 2 | Equity Incentive Plan
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number of options outstanding (in shares)	390,627
Vesting period	3 years
Vesting percentage	50.00%
Contractual life of options	8 years

Share based compensation - Di_2

Share based compensation - Disclosure of the fair value of options measured based on the Black-Scholes formula (Details)	12 Months Ended
	Dec. 31, 2018USD ($)
Equity Incentive Plan 2018 - October
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Share price at grant date (in USD per share)	$ 0.64
Exercise price (in USD per share)	$ 0.66
Expected volatility (as a percent)	137.06%
Expected dividends (as a percent)	0.00%
Risk-free interest rate	3.06%
Equity Incentive Plan 2018 - April
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Share price at grant date (in USD per share)	$ 1.46
Exercise price (in USD per share)	$ 1.58
Expected volatility (as a percent)	93.38%
Expected dividends (as a percent)	0.00%
Risk-free interest rate	2.92%
Equity Incentive Plan 2017 - October
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Share price at grant date (in USD per share)	$ 0.76
Exercise price (in USD per share)	$ 0.82
Expected volatility (as a percent)	72.85%
Expected dividends (as a percent)	0.00%
Risk-free interest rate	2.38%
Equity Incentive Plan 2017 - April
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Share price at grant date (in USD per share)	$ 0.72
Exercise price (in USD per share)	$ 0.82
Expected volatility (as a percent)	93.01%
Expected dividends (as a percent)	0.00%
Risk-free interest rate	2.19%
Board of Directors | Equity Incentive Plan 2018 - October
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Share price at grant date (in USD per share)	$ 0.340
Vesting period	1 year
Board of Directors | Equity Incentive Plan 2018 - April
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Share price at grant date (in USD per share)	$ 1.074
Vesting period	1 year
Board of Directors | Equity Incentive Plan 2017 - October
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Share price at grant date (in USD per share)	$ 0.198
Vesting period	1 year
Board of Directors | Equity Incentive Plan 2017 - April
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Share price at grant date (in USD per share)	$ 0.233
Vesting period	1 year
Tranche 1 | Employees/Board | Equity Incentive Plan 2018 - October
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Share price at grant date (in USD per share)	$ 0.449
Vesting period	2 years
Tranche 1 | Employees/Board | Equity Incentive Plan 2018 - April
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Share price at grant date (in USD per share)	$ 1.299
Vesting period	2 years
Tranche 1 | Employees/Board | Equity Incentive Plan 2017 - October
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Share price at grant date (in USD per share)	$ 0.287
Vesting period	2 years
Tranche 1 | Employees/Board | Equity Incentive Plan 2017 - April
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Share price at grant date (in USD per share)	$ 0.335
Vesting period	2 years
Tranche 2 | Employees/Board | Equity Incentive Plan 2018 - October
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Share price at grant date (in USD per share)	$ 0.514
Vesting period	3 years
Tranche 2 | Employees/Board | Equity Incentive Plan 2018 - April
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Share price at grant date (in USD per share)	$ 1.390
Vesting period	3 years
Tranche 2 | Employees/Board | Equity Incentive Plan 2017 - October
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Share price at grant date (in USD per share)	$ 0.352
Vesting period	3 years
Tranche 2 | Employees/Board | Equity Incentive Plan 2017 - April
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Share price at grant date (in USD per share)	$ 0.406
Vesting period	3 years

Share based compensation - Di_3

Share based compensation - Disclosure of the number and weighted average exercise prices of options (Details)	12 Months Ended
	Dec. 31, 2018CHF (SFr)sharesyear	Dec. 31, 2017CHF (SFr)sharesyear
Number of options
Beginning balance (in shares) | shares	225,154
Expired during the year (in shares) | shares	(5,000)
Forfeited during the year (in shares) | shares	(139,360)
Exercised during the year (in shares) | shares	0
Granted during the year (in shares) | shares	911,983
Ending balance (in shares) | shares	992,777	225,154
Exercisable (in shares) | shares	63,314
Weighted average exercise price
Beginning balance (in CHF per share) | SFr	SFr 17.40
Expired during the year (in CHF per share) | SFr	0
Forfeited during the year (in CHF per share) | SFr	0
Exercised during the year (in CHF per share) | SFr	0
Granted during the year (in CHF per share) | SFr	1.04
Ending balance (in CHF per share) | SFr	1.10	SFr 17.40
Exercisable (in CHF per share) | SFr	SFr 26.28
Weighted average remaining term
Beginning balance (term) | year	6.88
Granted during the year (term) | year	7.73
Ending balance (term) | year	7.45	6.88
Exercisable (term) | year	5.08
Reverse Stock Split
Number of options
Beginning balance (in shares) | shares	2,251,540	1,038,140
Expired during the year (in shares) | shares		(67,500)
Forfeited during the year (in shares) | shares		(637,200)
Exercised during the year (in shares) | shares		0
Granted during the year (in shares) | shares		1,918,100
Ending balance (in shares) | shares		2,251,540
Exercisable (in shares) | shares		326,510
Weighted average exercise price
Beginning balance (in CHF per share) | SFr	SFr 1.74	SFr 3.36
Expired during the year (in CHF per share) | SFr		0
Forfeited during the year (in CHF per share) | SFr		0
Exercised during the year (in CHF per share) | SFr		0
Granted during the year (in CHF per share) | SFr		0.82
Ending balance (in CHF per share) | SFr		1.74
Exercisable (in CHF per share) | SFr		SFr 4.48
Weighted average remaining term
Beginning balance (term) | year	6.88	6.14
Granted during the year (term) | year		7.70
Ending balance (term) | year		6.88
Exercisable (term) | year		4.24

Share based compensation - Meas

Share based compensation - Measurement of fair values (Details) - CHF (SFr)	Dec. 31, 2018	Dec. 31, 2017
Bottom of range
Disclosure of range of exercise prices of outstanding share options [line items]
Exercise price for outstanding options (in CHF per share)	SFr 0.66	SFr 0.80
Top of range
Disclosure of range of exercise prices of outstanding share options [line items]
Exercise price for outstanding options (in CHF per share)	SFr 59.8	SFr 5.81

Trade and other payables (Detai

Trade and other payables (Details) - CHF (SFr)	Dec. 31, 2018	Dec. 31, 2017
Subclassifications of assets, liabilities and equities [abstract]
Trade accounts payable - third parties	SFr 1,810,445	SFr 1,032,557
Other	25,890	168,263
Total trade and other payables	SFr 1,836,335	SFr 1,200,820

Accrued expenses (Details)

Accrued expenses (Details) - CHF (SFr)	Dec. 31, 2018	Dec. 31, 2017
Subclassifications of assets, liabilities and equities [abstract]
Accrued research and development costs including milestone payments	SFr 700,866	SFr 4,060,048
Professional fees	315,657	227,363
Accrued vacation & overtime	54,557	69,455
Employee benefits incl. share based payments	146,949	217,649
Other	72,850	108,198
Total accrued expenses	SFr 1,290,879	SFr 4,682,713

Research and development expe_3

Research and development expense (Details) - CHF (SFr)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Analysis of income and expense [abstract]
Pre-clinical projects	SFr 873,453	SFr 642,821	SFr 546,429
Clinical projects	846,235	12,365,768	16,639,304
Drug manufacturing and substance	2,185,292	2,027,184	2,608,814
Employee benefits and expenses	1,652,791	2,773,516	2,854,624
Lease expenses	65,921	111,680	84,344
Patents and trademarks	634,986	603,892	941,836
Regulatory projects	398,426	632,387	1,043,287
Depreciation tangible assets	32,485	53,594	58,125
Total research and development expense	SFr 6,689,589	SFr 19,210,842	SFr 24,776,763

General and administrative ex_3

General and administrative expense (Details) - CHF (SFr)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Analysis of income and expense [abstract]
Employee benefits and expenses	SFr 1,084,112	SFr 2,097,853	SFr 2,174,543
Business development	43,816	161,985	45,649
Travel expenses	70,944	199,484	158,774
Administration expenses	2,797,526	2,522,217	2,969,796
Lease expenses	52,416	81,277	63,695
Depreciation tangible assets	186,520	69,190	39,475
Capital tax expenses	29,200	18,403	(5,420)
Total general and administrative expenses	SFr 4,264,534	SFr 5,150,409	SFr 5,446,512

Employee benefits - Expense rec

Employee benefits - Expense recognized in statement of profit or loss (Details) - CHF (SFr)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Employee Benefits [Abstract]
Salaries	SFr 2,542,952	SFr 3,761,171	SFr 3,662,180
Pension costs	108,978	378,588	342,805
Other social benefits	188,138	277,468	301,537
Share based payments costs	27,730	354,851	290,783
Recruitment costs	0	125,731	391,035
Other personnel expenditures	(130,895)	(26,439)	40,827
Total employee benefits	SFr 2,736,903	SFr 4,871,370	SFr 5,029,167

Employee benefits - Narrative (

Employee benefits - Narrative (Details)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Employee Benefits [Abstract]
Minimum retirement saving interest rate (as a percent)	1.00%	1.00%	1.25%
Weighted average duration of defined benefit obligation	21 years 9 months 24 days	20 years 10 months 24 days

Employee benefits - Change in d

Employee benefits - Change in defined benefit obligation (Details) - CHF (SFr)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disclosure of net defined benefit liability (asset) [abstract]
Defined benefit obligation at January 1	SFr 1,962,970
Service costs	90,162	SFr 348,172	SFr 319,173
Interest cost	14,541	12,994	14,922
Defined benefit obligation at December 31	648,287	1,962,970
Present value of funded defined benefit obligation
Disclosure of net defined benefit liability (asset) [abstract]
Defined benefit obligation at January 1	7,999,617	7,122,841
Service costs	90,162	348,172
Plan participants' contribution	144,287	236,074
Interest cost	50,845	50,494
Actuarial losses	(1,911,382)	60,781
Transfer-out amounts	(3,367,834)	(440,950)
Transfer-in amounts of new employees	79,930	622,205
Defined benefit obligation at December 31	SFr 3,085,625	SFr 7,999,617	SFr 7,122,841

Employee benefits - Change in f

Employee benefits - Change in fair value of plan assets (Details) - CHF (SFr)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disclosure of net defined benefit liability (asset) [abstract]
Fair value of plan assets at January 1	SFr (1,962,970)
Interest income	(14,541)	SFr (12,994)	SFr (14,922)
Return on plan assets excluding interest income	(634,190)	332,759	23,835
Administration expense	(6,009)	(17,422)	(8,710)
Fair value of plan assets at December 31	(648,287)	(1,962,970)
Fair value of plan assets
Disclosure of net defined benefit liability (asset) [abstract]
Fair value of plan assets at January 1	6,036,647	5,030,407
Interest income	36,304	37,500
Return on plan assets excluding interest income	(634,190)	332,759
Employer contributions	146,245	236,074
Plan participants' contributions	146,245	236,074
Transfer-out amounts	(3,367,834)	(440,950)
Transfer-in amounts of new employees	79,930	622,205
Administration expense	(6,009)	(17,422)
Fair value of plan assets at December 31	SFr 2,437,338	SFr 6,036,647	SFr 5,030,407

Employee benefits - Net defined

Employee benefits - Net defined benefit liability (Details) - CHF (SFr)	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disclosure of net defined benefit liability (asset) [line items]
Net defined benefit liability	SFr 648,287	SFr 1,962,970
Present value of funded defined benefit obligation
Disclosure of net defined benefit liability (asset) [line items]
Net defined benefit liability	3,085,625	7,999,617	SFr 7,122,841
Fair value of plan assets
Disclosure of net defined benefit liability (asset) [line items]
Net defined benefit liability	SFr (2,437,338)	SFr (6,036,647)	SFr (5,030,407)

Employee benefits - Defined ben

Employee benefits - Defined benefit costs recognized in profit or loss (Details) - CHF (SFr)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Employee Benefits [Abstract]
Service costs	SFr 90,162	SFr 348,172	SFr 319,173
Net interest expense	14,541	12,994	14,922
Administration expense	6,009	17,422	8,710
Total defined costs for the year recognized in profit or loss	SFr 110,712	SFr 378,588	SFr 342,805

Employee benefits - Remeasureme

Employee benefits - Remeasurement of defined benefit liability (Details) - CHF (SFr)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Employee Benefits [Abstract]
Actuarial loss (gain) arising from changes in financial assumptions	SFr (119,117)	SFr (150,552)	SFr 412,396
Actuarial loss arising from experience adjustments	(1,792,265)	211,331	264,417
Actuarial gain arising from demographic assumptions	0	0	(258,876)
Return on plan assets excluding interest income	634,190	(332,759)	(23,835)
Total defined benefit cost for the year recognized in the other comprehensive loss	SFr (1,277,192)	SFr (271,980)	SFr 394,102

Employee benefits - Assumptions

Employee benefits - Assumptions (Details)	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Employee Benefits [Abstract]
Discount rate	0.95%	0.80%	0.70%
Future salary increase	1.10%	1.10%	1.10%
Pension indexation	0.00%	0.00%	0.00%

Employee benefits - Sensitivity

Employee benefits - Sensitivity Analysis (Details) - CHF (SFr)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Discount rate
Disclosure of defined benefit plans [line items]
Percentage of reasonably possible increase in actuarial assumption	0.25%	0.25%
Increase (decrease) in defined benefit obligation due to reasonably possible increase in actuarial assumption	SFr (138,606)	SFr (354,477)
Salary increase
Disclosure of defined benefit plans [line items]
Percentage of reasonably possible increase in actuarial assumption	0.25%	0.25%
Increase (decrease) in defined benefit obligation due to reasonably possible increase in actuarial assumption	SFr 13,121	SFr 49,707
Pension indexation
Disclosure of defined benefit plans [line items]
Percentage of reasonably possible increase in actuarial assumption	0.25%	0.25%
Increase (decrease) in defined benefit obligation due to reasonably possible increase in actuarial assumption	SFr 65,943	SFr 189,965
Life expectancy
Disclosure of defined benefit plans [line items]
Increase (decrease) in defined benefit obligation due to reasonably possible increase in actuarial assumption	SFr 60,369	SFr 182,977
Life expectancy reasonably possible increase in actuarial assumption	1 year	1 year

Finance income and finance ex_3

Finance income and finance expense - Components of finance income (expense) (Details) - CHF (SFr)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Analysis of income and expense [abstract]
Interest income	SFr 0	SFr 53,570	SFr 67,565
Net foreign currency exchange gain	1,103,067	1,912,681	843,950
Revaluation gain from derivative financial instruments	1,350,071	3,372,186	291,048
Total finance income	2,453,138	5,338,437	1,202,563
Interest expense (incl. Bank charges)	1,070,177	1,640,394	828,547
Net foreign currency exchange loss	1,242,938	2,737,273	944,047
Total finance expense	2,313,115	4,377,667	1,772,594
Finance income/(expense), net	SFr 140,023	SFr 960,770	SFr (570,031)

Finance income and finance ex_4

Finance income and finance expense - Narrative (Details) - CHF (SFr)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disclosure of Finance Income (Expense) [Line Items]
Net foreign currency exchange gain	SFr 1,103,067	SFr 1,912,681	SFr 843,950
Interest expense on borrowings	435,993	1,182,369	546,170
USD and EUR denominated cash and cash equivalents
Disclosure of Finance Income (Expense) [Line Items]
Net foreign currency exchange gain	SFr 264,029	SFr 1,315,029	SFr 396,665

Taxation - Income tax provision

Taxation - Income tax provision (Details) - CHF (SFr)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Income Taxes [Abstract]
Deferred income tax expense	SFr (294,056)	SFr (21,415)	SFr 0
Deferred income tax gain	131,879	39,188	131,055
Income tax gain	SFr (162,177)	SFr 17,773	SFr 131,055
Average effective tax rate (as a percent)	21.10%	21.70%	21.50%

Taxation - Reconciliation of in

Taxation - Reconciliation of income tax expense (income) (Details) - CHF (SFr)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Income Taxes [Abstract]
Loss before income tax	SFr (11,334,224)	SFr (24,427,247)	SFr (30,793,306)
Income tax at statutory tax rates applicable to results in the respective countries	2,397,177	5,311,030	6,629,237
Effect of unrecognized temporary differences	140,371	193,598	(27,072)
Effect of unrecognized taxable losses	(2,553,594)	(5,429,935)	(6,360,837)
Effect of previously unrecognised deferred tax asset	114,116	39,189	131,055
Effect of expenses deductible for tax purposes	0	9,696	2,505
Effect of expenses not considerable for tax purposes	0	0	23,716
Effect of impact from application of different tax rates	(260,247)	(105,805)	(267,695)
Effect of unrecognized taxable losses in equity	0	0	146
Income tax gain	SFr (162,177)	SFr 17,773	SFr 131,055

Taxation - Deferred tax assets

Taxation - Deferred tax assets and liabilities (Details) - CHF (SFr)	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deferred tax liabilities	SFr (646,192)	SFr (396,529)
Deferred tax assets	305,206	217,720
Deferred tax liability (asset)	(340,986)	(178,809)	SFr (196,582)
Intangible assets
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deferred tax liabilities	(627,540)	(349,052)
Deferred tax liability (asset)	(627,540)	(349,052)	(327,637)
Hercules Loan Facility
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deferred tax liabilities	(889)	(47,477)
Deferred tax liability (asset)	(889)	(47,477)
Derivative financial instruments
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deferred tax liabilities	(17,763)
Deferred tax liability (asset)	(17,763)
Net operating loss (NOL)
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deferred tax assets	305,206	217,720
Deferred tax liability (asset)	SFr 305,206	SFr 217,720	SFr 207,445

Taxation - Deferred tax rollfor

Taxation - Deferred tax rollforward (Details) - CHF (SFr)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Reconciliation of changes in deferred tax liability (asset) [abstract]
Opening Balance	SFr (178,809)	SFr (196,582)
Recognized in Profit or Loss	(162,177)	17,773
Recognized in Equity	0	0
Closing Balance	(340,986)	(178,809)
Intangible assets
Reconciliation of changes in deferred tax liability (asset) [abstract]
Opening Balance	(349,052)	(327,637)
Recognized in Profit or Loss	(276,293)	(21,415)
Recognized in Equity	(2,195)	0
Closing Balance	(627,540)	(349,052)
Hercules Loan Facility
Reconciliation of changes in deferred tax liability (asset) [abstract]
Opening Balance	(47,477)	(76,390)
Recognized in Profit or Loss		28,913
Recognized in Equity		0
Closing Balance		(47,477)
Hercules Loan Facility
Reconciliation of changes in deferred tax liability (asset) [abstract]
Opening Balance	(47,477)
Recognized in Profit or Loss	46,588
Recognized in Equity	0
Closing Balance	(889)	(47,477)
Derivative financial instruments
Reconciliation of changes in deferred tax liability (asset) [abstract]
Recognized in Profit or Loss	(17,763)
Closing Balance	(17,763)
Net operating loss (NOL)
Reconciliation of changes in deferred tax liability (asset) [abstract]
Opening Balance	217,720	207,445
Recognized in Profit or Loss	85,291	10,275
Recognized in Equity	2,195	0
Closing Balance	SFr 305,206	SFr 217,720

Taxation - Unrecognized tax los

Taxation - Unrecognized tax losses (Details) - CHF (SFr)	Dec. 31, 2018	Dec. 31, 2017
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Tax loss carry forwards	SFr 151,362,039	SFr 141,970,938
Within one year
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Tax loss carry forwards	8,173,993	1,754,398
Between 1 and 3 years
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Tax loss carry forwards	41,980,704	31,089,191
Between 3 and 7 years
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Tax loss carry forwards	100,136,349	108,055,089
More than 7 years
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Tax loss carry forwards	1,070,993	1,072,260
Switzerland
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Tax loss carry forwards	150,300,000	140,900,000
United States
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Tax loss carry forwards	SFr 1,100,000	SFr 1,100,000

Taxation - Unrecognized deducti

Taxation - Unrecognized deductible temporary differences and tax losses (Details) - CHF (SFr)	Dec. 31, 2018	Dec. 31, 2017
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deductible temporary differences	SFr 291,678	SFr 834,580
Taxable unrecognized temporary differences	0	0
Potential tax assets from loss carry-forwards not recognized	31,387,022	29,959,963
Total potential tax assets from loss carry-forwards and temporary differences not recognized	31,678,700	30,794,543
Employee benefit plan
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deductible temporary differences	143,271	433,816
Stock option plans
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deductible temporary differences	148,407	400,764
Property and equipment
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Taxable unrecognized temporary differences	0	0
Before Offset Amount
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deductible temporary differences	291,678	834,580
Offset Amount
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Offsetting potential tax liabilities with potential tax assets	SFr 0	SFr 0

Loss per share (Details)

Loss per share (Details)	Mar. 13, 2018	Dec. 31, 2018CHF (SFr)sharesSFr / shares	Dec. 31, 2017CHF (SFr)sharesSFr / shares	Dec. 31, 2016CHF (SFr)SFr / sharesshares
Earnings per share [abstract]
Loss attributable to owners of the Company | SFr		SFr (11,496,401)	SFr (24,409,474)	SFr (30,662,251)
Weighted average number of shares outstanding		15,900,865	4,374,187	3,432,928
Basic and diluted loss per share (in chf per share) | SFr / shares		SFr (0.72)	SFr (5.58)	SFr (8.93)
Earnings per share [line items]
Reverse-split ratio	10
Options outstanding (in shares)		992,777	225,154
Employee Stock Options
Earnings per share [line items]
Options outstanding (in shares)		992,777
Antidilutive securities excluded from computation of earnings per share (in shares)		459,645	1,676,526
Warrants
Earnings per share [line items]
Antidilutive securities excluded from computation of earnings per share (in shares)		6,544,791

Commitments and contingencies_2

Commitments and contingencies (Details) - CHF (SFr)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disclosure of finance lease and operating lease by lessee [line items]
Minimum finance lease payments payable	SFr 24,374	SFr 607,161
Office lease expense	118,337	192,957	SFr 148,039
Within one year
Disclosure of finance lease and operating lease by lessee [line items]
Minimum finance lease payments payable	24,374	161,110
Between one and five years
Disclosure of finance lease and operating lease by lessee [line items]
Minimum finance lease payments payable	SFr 0	SFr 446,051

Loan and warrant (Details)

Loan and warrant (Details)	Apr. 05, 2018USD ($)	Mar. 13, 2018$ / sharesshares	Feb. 21, 2017SFr / sharesshares	Jul. 19, 2016USD ($)$ / sharesshares	Dec. 31, 2018CHF (SFr)	Dec. 31, 2017CHF (SFr)	Apr. 05, 2018CHF (SFr)
Disclosure of detailed information about borrowings [line items]
Liquidity covenant amount | $	$ 5,000,000
Repayments of current borrowings | $	5,000,000
Collateral cash | $	$ 2,120,257
Recognized loss on loan and transaction costs | SFr							SFr 334,747
Warrants issued (in shares) | shares			7,945,000
Exercise price of warrants (in dollars per share) | SFr / shares			SFr 1.2
Secured term loan facility
Disclosure of detailed information about borrowings [line items]
Term loan facility (up to) | $				$ 20,000,000
Drawn on term loan facility				$ 12,500,000	SFr 1,435,400
Exercise price of warrants (in dollars per share) | $ / shares				$ 3.94
Warrants exercisable (in shares) | shares				156,726
Number of additional warrants exercisable upon second advance (in shares) | shares				84,391
Secured term loan facility | Floating interest rate | Minimum
Disclosure of detailed information about borrowings [line items]
Interest rate per annum (as a percent)				9.55%
Within one year | Secured term loan facility
Disclosure of detailed information about borrowings [line items]
Amortization payments | SFr					1,435,400
Warrants | Secured term loan facility
Disclosure of detailed information about borrowings [line items]
Exercise price of warrants (in dollars per share) | $ / shares		$ 39.40
Fair value of warrants | SFr					3,804
Gain recognized upon change in fair value of warrants | SFr					SFr 19,546	SFr 93,782
Number of common shares exercisable through warrants, up to (in shares) | shares		15,673		241,117

Related party transactions (Det

Related party transactions (Details)	12 Months Ended
	Dec. 31, 2018CHF (SFr)shares	Dec. 31, 2017CHF (SFr)shares	Dec. 31, 2016CHF (SFr)shares
Disclosure of transactions between related parties [line items]
Short term benefits	SFr 1,203,128	SFr 1,857,626	SFr 1,880,343
Post-employee benefits years	55,278	94,839	88,838
Share-based payment charge	264,881	263,306	321,361
Total	SFr 1,523,287	SFr 2,215,771	2,290,542
Number of options outstanding (in shares) | shares	992,777	225,154
Number of share options granted (in shares) | shares	911,983
Grant price (in USD per share)	SFr 1.04
Payroll charge	27,730	SFr 354,851	290,783
Executive Management
Disclosure of transactions between related parties [line items]
Total compensation paid to management	1,403,250	1,973,167	1,871,406
Short term benefits	1,002,707	1,576,864	1,554,850
Post-employee benefits years	55,278	94,839	88,838
Share-based payment charge	204,224	190,659	217,981
Total	1,262,209	1,862,362	1,861,669
Board of Directors
Disclosure of transactions between related parties [line items]
Total compensation paid to management	287,384	337,619	364,276
Short term benefits	200,421	280,762	325,493
Post-employee benefits years	0	0	0
Share-based payment charge	60,657	72,647	103,380
Total	SFr 261,078	SFr 353,409	SFr 428,873
Number of options outstanding (in shares) | shares	703,235	1,782,605	656,355
Equity Incentive Plan
Disclosure of transactions between related parties [line items]
Number of share options granted (in shares) | shares	911,983	1,918,100
Equity Incentive Plan | Restricted shares
Disclosure of transactions between related parties [line items]
Number of share options granted (in shares)		0

Warrants from Public Offering (

Warrants from Public Offering (Details)	Jul. 17, 2018CHF (SFr)SFr / sharesshares	Mar. 13, 2018SFr / shares$ / sharesshares	Jan. 30, 2018CHF (SFr)SFr / sharesshares	Feb. 21, 2017USD ($)shares	Feb. 21, 2017CHF (SFr)SFr / sharesshares	Dec. 31, 2017CHF (SFr)SFr / sharesshares	Dec. 31, 2018CHF (SFr)SFr / sharesshares	Dec. 31, 2017CHF (SFr)SFr / sharesshares	Dec. 31, 2016CHF (SFr)SFr / shares
Disclosure of classes of share capital [line items]
Nominal value (in CHF per share) | SFr / shares						SFr 0.40	SFr 0.02	SFr 0.40
Share issue related cost									SFr 1,862
Transaction costs recognized in equity							SFr 1,259,587	SFr 521,515
Transaction costs recognized in profit or loss							SFr 520,125	SFr 1,026,766	SFr 0
Warrants issued (in shares) | shares				7,945,000	7,945,000
Exercise price (in USD per share) | SFr / shares					SFr 1.2
Series B Warrants
Disclosure of classes of share capital [line items]
Number of shares issued (in shares) | shares	4,487,178
Common shares issued (in shares) | shares							2,864,422
Gross proceeds							SFr 1,117,125
Warrants outstanding							SFr 2,864,422
Common shares nominal value
Disclosure of classes of share capital [line items]
Number of shares issued (in shares) | shares						48,373,890	35,516,785	48,373,890
Nominal value (in CHF per share) | SFr / shares						SFr 0.40	SFr 0.02	SFr 0.40	SFr 0.40
Warrants
Disclosure of classes of share capital [line items]
Exercise price (in USD per share) | SFr / shares			SFr 0.50
Number of common shares exercisable through warrants, up to (in shares) | shares		750,002
Exercise price of warrants (in CHF per share) | SFr / shares		SFr 5
Warrants outstanding (in shares) | shares			7,499,999
Issuance initial public offering (in shares) | shares			12,499,999
Series A Warrants
Disclosure of classes of share capital [line items]
Number of shares issued (in shares) | shares	6,282,051
Common shares issued (in shares) | shares	17,948,717						2,904,518
Nominal value (in CHF per share) | SFr / shares	SFr 0.02
Gross proceeds							SFr 1,132,762
Warrants
Disclosure of classes of share capital [line items]
Nominal value (in CHF per share) | SFr / shares	SFr 0.39
Public offering
Disclosure of classes of share capital [line items]
Conversion ratio				0.70	0.70
Net proceeds after underwriting discounts				$ 9,100,000	SFr 9,100,000
Share issue related cost					903,919
Transaction costs recognized in equity					397,685
Transaction costs recognized in profit or loss					SFr 506,234
Period of option to purchase additional common shares and/or additional warrants				30 days	30 days
Gross proceeds				$ 10,000,000	SFr 9,998,305
Public offering | Common shares nominal value
Disclosure of classes of share capital [line items]
Number of shares issued (in shares) | shares					10,000,000
Nominal value (in CHF per share) | SFr / shares					SFr 0.40
Additional equity available for purchase (up to) (in shares) | shares				1,500,000	1,500,000
Gross proceeds					SFr 4,906,488
Public offering | Warrants
Disclosure of classes of share capital [line items]
Number of shares issued (in shares) | shares					10,000,000
Additional equity available for purchase (up to) (in shares) | shares				1,500,000	1,500,000
Additional warrants purchased (in shares) | shares				1,350,000	1,350,000
Gross proceeds					SFr 5,091,817
Shares subject to revaluation | Series B Warrants
Disclosure of classes of share capital [line items]
Warrants outstanding							690,702
February 2017 Offering | Warrants
Disclosure of classes of share capital [line items]
Exercise price (in USD per share) | $ / shares		SFr 12
Number of common shares exercisable through warrants, up to (in shares) | shares		794,500
At fair value
Disclosure of classes of share capital [line items]
Warrants outstanding						SFr 1,813,413	166,301	SFr 1,813,413
Decrease in fair value of warrants						SFr (1,647,112)
At fair value | Series B Warrants
Disclosure of classes of share capital [line items]
Warrants outstanding							3,005,348
Decrease in fair value of warrants	SFr 572,249						2,433,098
At fair value | Warrants
Disclosure of classes of share capital [line items]
Warrants outstanding			SFr 2,483,747				289,651
Decrease in fair value of warrants							(2,194,096)
At fair value | Shares subject to revaluation | Series B Warrants
Disclosure of classes of share capital [line items]
Warrants outstanding	SFr 137,987						215,572
Decrease in fair value of warrants							SFr 77,585

Events after the balance shee_2

Events after the balance sheet date (Details) - Ordinary shares - USD ($)	Mar. 14, 2019	Dec. 31, 2018	Dec. 31, 2017
Disclosure of classes of share capital [line items]
Number of shares issued (in shares)		35,516,785	48,373,890
At-the-market Agreement
Disclosure of classes of share capital [line items]
Number of shares issued (in shares)	1,979,074
Proceeds from IPO, net of underwriting fees and IPO costs	$ 978,415